2015N242468_02 CONFIDENTIA L
TheGlaxoSmithKline group of companies 204851
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A multi -centre Phase IIa double -blind, placebo -controlled study  
to investigate the efficacy and safet y of [COMPANY_004]3196165 in subjects 
with inflammatory  hand osteoarthritis.
Compound Number: [COMPANY_004]3196165
Development Phase: IIa
Effective Date: 03-JAN-2017
Protocol Amendment Number: 2
Author (s):  
 
Copy right [ADDRESS_667723]- treatment interview guidance.
2015N242468_02 2017- JAN-03 Amendment No. 2
Amendment of inclusion criteria , #2, #3 and #5, c larification of exclusion criteria #9 and 
amendment of exclusion criteria #19(d).
Addition of two planned interim analy ses to Section 9.3 and associated update to study  
blinding details (Section 6.4).
Addition of two PK sampl e time points (one on Day  85and one on Day 155).
Further minor corrections and clarifications to wording throughout the protocol .See 
Appendix 1 4for full details . 2017N347456_00
 2017N347456_00
[COMPANY_003]
[COMPANY_003]
2015N242468_02 CONFIDENTIA L
204851
4MEDICA L MONITOR/SPON SOR INFORM ATION PA GE
Medical Monitor/SAE Contact [CONTACT_7171]: 
Role Name [CONTACT_428260] -hours 
Phone/Cell/
Pager 
NumberFax Number Site Address
Primary 
Medical 
Monitor [COMPANY_004] Medicines 
Research Centre,
Gunnels Wood 
Road, Stevenage, 
Herts. SG1 2NY
Secondary 
Medical 
Monitor[COMPANY_004],
Ironbridge Road,
Stockley Park 
West, Uxbridge.
UB11 1BT 
Sponsor Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_667724]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_515284].   
Regulatory Agency Identifying Number(s):
EudraCT number – 2015-003089-[ADDRESS_667725] igator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782] 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
6TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 204851 ...................................................... 10
2.INTRODUCTION .................................................................................................... 12
2.1. Study Rationale .......................................................................................... 12
2.2. Brief Background ................................
........................................................ 13
2.2.1. Hand osteoarthritis ....................................................................... 13
2.2.2. GM-CSF and OA ......................................................................... 13
2.2.3. [COMPANY_004]3196165 ............................................................................... 14
2.2.4. Clinical Data ................................................................................ 14
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 15
4.STUDY DESIGN .................................................................................................... 17
4.1. Overall Design ............................................................................................ 17
4.2. Study Schematic ......................................................................................... 17
4.2.1. Pharmacokinetics ........................................................................ 18
4.2.2. Biomarkers .................................................................................. 18
4.3. Treatment Arms and Duration ..................................................................... 18
4.4. Type and Number of Subjects ..................................................................... 19
4.5. Design Justification ..................................................................................... 19
4.6. Dose Justification ........................................................................................ 20
4.7. Benefit:Risk Assessment ............................................................................ 22
4.7.1. Risk Assessment ......................................................................... 23
4.7.2. Benefit Assessment ..................................................................... 30
4.7.3. Overall Benefit:Risk Conclusion ................................................... [ADDRESS_667726] AWAL CRITERIA ............. 30
5.1. Inclusion Criteria ......................................................................................... 31
5.2. Exclusion Criteria ........................................................................................ 32
5.3. Screening/Baseline/Run -in Failures ............................................................ 35
5.3.1. Re-Screening ............................................................................... 35
5.3.2. Re-Testing –Laboratory Exclusion .............................................. 35
5.4. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... 35
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 36
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_667727] and Other Study Treatment .................................... 39
6.2. Treatment Assignment ................................................................................ 40
6.3. Planned Dose Adjustments ......................................................................... 41
6.4. Blinding ....................................................................................................... 41
6.5. Packaging and Labelling ............................................................................. 42
6.6. Preparation/Handling/Storage/Accountability .............................................. [ADDRESS_667728] awal* procedures list ................... [ADDRESS_667729]’s Assessment of Hand Pain, Function, Stiffness, 
and Subject’s / Cl inician’s Assessment of Global Disease 
Activity ......................................................................................... 51
7.4. Safety ......................................................................................................... 52
7.4.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 52
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 52
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 53
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 53
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 53
[IP_ADDRESS]. Regulatory Reporting Requirements for SAEs ............ [ADDRESS_667730] (AESIs) ................................................... 54
7.4.3. Pregnancy ................................................................................... 54
7.4.4. Physical Exams ........................................................................... 54
7.4.5. Vital Signs .................................................................................... 55
7.4.6. Electrocardiogram (ECG) ............................................................. [ADDRESS_667731]-treatment Interviews ............................................................ 60
8.DATA MANAGEMENT ........................................................................................... 60
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .60
9.1. Hypotheses ................................................................................................ .60
9.2. Sample Size Considerations ....................................................................... 61
9.2.1. Sample Size Assumptions ........................................................... 61
9.2.2. Sample Size Sensitivity ................................................................ 61
9.2.3. Sample Size Re- estimation or Adjustment ................................... 61 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
89.3. Data Analysis Considerations ..................................................................... 61
9.3.1. Analysis Populations .................................................................... 61
9.3.2. Interim Analysis ........................................................................... 61
9.4. Key Elements of Analysis Plan ................................................................... 62
9.4.1. Primary Analyses ......................................................................... 62
9.4.2. Secondary Analyses .................................................................... 62
9.4.3. Other Analyses ............................................................................ 63
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 63
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 63
10.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 63
10.3. Quality Control (Study Monitoring) .............................................................. 64
10.4. Quality Assurance ....................................................................................... 64
10.5. Study and Site Closure ............................................................................... 64
10.6. Records Retention ...................................................................................... 65
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 66
11.REFERENCES ....................................................................................................... 67
12.APPENDICES ........................................................................................................ 72
12.1. Appendix 1 –Abbreviations and Trademarks .............................................. 72
12.2. Appendix 2 –Liver Safety Required Action s and Follow up 
Assessments .............................................................................................. 76
12.3. Appendix 3 –Genetic Research ................................................................ .79
12.4. Appendix 4 –Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of Adverse Events ............................ 82
12.4.1. Definition of Adverse Events ........................................................ 82
12.4.2. Definition of Serious Adverse Events ........................................... 83
12.4.3. Definitio n of Cardiovascular Events ............................................. 84
12.4.4. Recording of AEs and SAEs ........................................................ 85
12.4.5. Evaluating AEs and SAEs ............................................................ 85
12.4.6. Reporting of SAEs to [COMPANY_004] ........................................................... 87
12.5. Appendix 5 –Contraception eligibility criteria for female and male 
subjects ...................................................................................................... 88
12.5.1. Males:.......................................................................................... 88
12.5.2. Females: ...................................................................................... [ADDRESS_667732] of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potenti al (FRP) .............. 89
12.5.4. Collection of Pregnancy Information (female subjects) ................. 90
12.5.5. Collection of Pregnancy Information (female partners of 
male subjects) ............................................................................. 90
12.6. Appendix 6 –Recommended Pulmonary Assessment Algorithms .............. 91
12.6.1. Follow -up Algorithms ................................................................... 91
12.6.2. Management of Study Medications During Pulmonary 
Assessment ................................................................................. 92
12.6.3. Central Review of P ulmonary Investigations ................................ 92
12.6.4. Adjudication Process for Suspected Cases of Pulmonary 
Alveolar Proteinosis ..................................................................... 93
12.7. Appendix 7 –Common Terminology Criteria for Adverse Events 
(CTCAE): Cough ......................................................................................... 94 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
912.8. Appendix 8 –Average Pain NRS ................................................................ 95
12.9. Appendix 9 –Worst Pain NRS .................................................................... 96
12.10. Appendix 10 –Patient Global Assessment of Disease Activity 
(PtGA) ........................................................................................................ 97
12.11. Appendix 11 –Physician Global Assessment of Disease Activity 
(PhGA) ....................................................................................................... 98
12.12. Appendix 12 –Patient Post -Treatment Interview ........................................ 99
12.13. Appendix 13 –Country Specific Requirements ......................................... 103
12.14. Appendix 14 –Protocol Amendment Changes .......................................... 104 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
101. PROTOCOL SYNOPSIS FOR STUDY 204851
Rationale
This study  is designed to investigate whether [COMPANY_004]3196165 may  offer a treatment benefit 
for subjects with inflammatory  hand osteoarthritis (HOA ).
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To assess the efficacy potential of 
[COMPANY_004]3196165 on pain in inflammatory 
HOA.Change from baseline in 24h average hand pain 
intensity at Week 6, as measured by [CONTACT_515285] (NRS) averaged over the 
7 days prior to assessment visit.
Secondary
To evaluate impact of [COMPANY_004]3196165 
on average and worst HOA pain, over 
time.Change from baseline in 24h average hand pain 
intensity at each visit, measured by [CONTACT_515286] 7 days prior to each 
assessment visit. 
Change from baseline of worst hand pain 
intensity over 24h at each visit, measured by 
[CONTACT_515287] 7 days prior to 
each assessment visit. 
Proportion of subjects in each treatment group 
achieving a 30% reduction in 24h average hand 
pain intensity at each visit, measured by [CONTACT_515288] 7 days prior to 
assessment visit.
Proportion of subjects in each treatment group 
achieving a 50% reduction in 24h average hand 
pain intensity at each visit, measured by [CONTACT_515288] 7 days prior to 
assessment visit. 
Proportion of subjects in each treatment group 
achievin g a 30% reduction in 24h worst hand 
pain intensity at each visit, measured by [CONTACT_515288] 7 days prior to 
assessment visit.
Proportion of subjects in each treatment group 
achieving a 50% reduction in 24h worst hand 
pain intensity at each visit, measured by [CONTACT_515288] 7 days prior to 
assessment visit.
To assess the impact of [COMPANY_004]3196165 
on hand pain (on use), stiffness and 
function, over time.Change from baseline in Australian Canadian 
Hand Osteoarthritis Index (AUSCAN) 3.1 NRS, 
total and domains (pain, morning stiffness, 
function) scores at each visit.  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
11Objectives Endpoints
To assess the impact of [COMPANY_004]3196165 
on HOA inflammation Change in number of swollen and tender hand 
joints at each visit.
To assess potential impact of 
[COMPANY_004]3196165 on disease activity in 
HOA,Change from baseline in patient global 
assessment (PtGA) and physician global 
assessment (PhGA) of disease activity at Week 
6,12 and 22.
To assess safety of [COMPANY_004]3196165 in 
HOA patients, over the study duration.Incidence of adverse events and serious adverse 
events.
Incidence of infections.
Incidence of pulmonary events (cough/dyspnea, 
PAP and D LCO).
Immunogenicity.
To assess population 
pharmacokinetics of [COMPANY_004]3196165 in 
HOA.Population pharmacokinetics endpoints such as 
CL/F, Vss/F, Ka.
* If only one hand is affected by [CONTACT_515289], the affected hand will be documented at 
screening and used for all assessments. In cases where both hands are affected by [CONTACT_515290], then the dominant hand will be documented at screening and this hand will be used for all single -
hand assessments throughout the study.
Overall Design
This is a randomized Phase IIa, multicentre, double -blind, placebo -controlled parallel 
group stud y with the prima ry objective to assess the efficacy potential of [COMPANY_004]3196165 
on pain, in subjects with active inflammatory  HOA.
Stud y schematic
Primary endpoi nt 
pain at week 6Basel ine pain, function, 
tender  and swollen 
joints, biomar kers, 
safet y and laboratory 
evaluations. Efficacy (pain, 
funct ion, imaging)  and 
safet y at week 125 loadin g doses (Day 1, 8, 15, 22, 29) followed 
by 3 doses every oth er week (D ay 43, 57, 71).
Safet y evaluation, 
MRI and Pain at 
week  22Dosing: [COMPANY_004] 3196165 or Placebo 
(1:1 randomised)
D 43 
(Week 6)
D 85 
(Week 12)
D 155 
(Week 22)D 1
(Week 0)Treatment period
•Pain , function, imaging, PKFollow up period
•Pain , imaging, safetyD 8  
D 15
D 22
D 29
D 57
D 71Screening
Period
•ACR 
classification, 
MRI, Pain, 
tender and 
swollen  joints 
and Safet y 
evalu ationsD -28 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
12Treatment A rms and Duration
A screening period of up to 4 weeks, will be followed b y a 12 week treatment period 
(dosing with [COMPANY_004]3196165 or placebo) then a follow up period, completing on week 
22. The total study  duration for an individual subject will be approximately 26 
weeks. 
The Study  consists of 2 arms: treatment with [COMPANY_004]3196165 or placebo will be given 
as a single subcutaneous injection (shielded to subjects) to the abdomen or thigh, b y 
an unblinded administrator weekl y for 5 injections, from Week 0 to Week 4 (Days 1, 
8, 15, 22, 29), then every other week for 3 further injections, from Week 6 until 
Week 10 (Day s 43, 57 and 71).  
In total, each subject will receive up to [ADDRESS_667733] 40 subjects will be randomized 
across the two treatment arms, to either placebo or [COMPANY_004]3196165, in a 1:1 ratio (n=20 per 
arm).  
Analysis
The study  will test the null hy pothesis that there is no difference between 
[COMPANY_004]3196165 and placebo in the change from baseline in the 24h average Pain 
Numerical Rating Scale (NRS) at Week [ADDRESS_667734].
The primary  endpoint of the study  is change from baseline in 24h average hand pain 
intensity  at Week 6, as measured by  [CONTACT_515291] (NRS) 
averaged over the 7 day s prior to assessment visit.
The primary  endpoint will be anal ysed using a repeated measures model (MMRM) 
adjusted for baseline pain score, treatment group, visit and the visit by  [CONTACT_515292], patient as a random e ffect and day within patient 
as a repeated effect, using an unstructured covariance matrix.
2. INTRODUCTION
[COMPANY_004]3196165 is a novel human monoclonal antibody  which inhibits granulocy te-
macrophage colon y stimulating factor (GM -CSF) and is being developed for the
treatment of rheumatoid arthritis (RA) and other inflammatory  diseases.
2.1. Stud y Rationale
This study  is designed to investigate whether [COMPANY_004]3196165 may  offer a treatment benefit 
for subjects with inflammatory  hand osteoarthritis. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
132.2. Brief Background
2.2.1. Hand osteoa rthritis
Hand osteoarthritis (HOA) is the second most common form of osteoarthritis (OA) which 
is itself, the most common musculoskeletal disorder.  The factors underl ying the 
relationship between inflammatory  and erosive HOA are not fully  understood, though it 
seems likely  that erosions could be a consequence of chronic inflammation. The 
presentation of HOA is typi[INVESTIGATOR_515245] s ymptoms reflecting underly ing inflammation in 
the proximal joints of the hand affecting the s ynovium, cartilage and bone. Severe han d 
pain can significantl y impair day to day activities through functional impairment in the 
form of stiffness, reduced grip strength, reduced hand mobility , and difficulty  performing 
dexterous tasks. Some patients have demonstrable bony  erosions on X -Ray orMagnetic 
Resonance Imaging (MRI) [ Kortekaas , 2015 and Kwok , 2011]. Erosive disease has the 
potential to irreversibl y destroy joint architecture and result in permanent disability . 
Treatment options for both inflammatory  and erosive HOA are limited and are focused 
on alleviating s ymptoms through pain medication, local steroid injections and surgical 
intervention but provide limited, if any , benefit.[ Gelber , 2015; Chevalier , 2014; Bijlsma , 
2011; Altman, 2010 and Towheed , 2005]  Hence there is a clear unmet need to develop 
new therapeutics which not only  address sy mptoms but also result in disease modification 
such as reduction in structural joint d amage or prevention of inflammatory  changes in the 
joints which can lead to deterioration of long term functional ability . 
2.2.2. GM-CSF and OA
The pathogenic characteristics of OA are loss of cartilage with associated underly ing 
bony  changes consisting of sclerosis, sub -chondral bone collapse, bone cy sts and 
osteophy te formation [ Iannone , 2003]. Pain is one of the most important symptoms of 
OA as it causes a significant impairment in function. The etiology  of OA is likely  to be 
multifactorial, and recent histological evidence indicates that s ynovi tis is an earl y feature 
in OA, even in joints where it could not be detected clinically  [Spector , 1997; Sowers , 
2002; Haywood , 2003], with a mixed inflammatory  infiltrate consisting mainly  of 
macrophages and with pro- inflammatory  mediator production (e.g. TNF, IL -1b) [ Farahat , 
1993; Bondeson , 2010]. It has been argued that OA sy novial inflammation is 
qualitatively  similar to that in RA, differi ng onl y in magnitude [ Haraoui , 1991].
Granulocy te-macrophage colony  stimulating factor receptor (GM
-CSFR) is expressed in 
OA sy novium [ Berenbaum , 1994] and is spontaneously  produced b y OA s ynovial cell 
cultures over a time course of 5 day s [Haworth , 1991]. GM- CSF induces the proliferation 
and activation of macrophage lineage cells leading to strongl y increased production of 
key proinflammatory  cytokines (including TNFα, IL -6, and IL -1), chemokines and matr ix 
degrading proteases [ Fleetwood , 2007; Gasson , 1991; Hamilton , 2004; Hamilton , 2013; 
Hart, 1991; Mantovani , 2007].  GM- CSF also serves as a differentiation factor for 
dendritic cells and induces upregulation of human ly mphocy teantigen (HLA) class II on 
antigen presenting cells, which in turn will activate CD4+ T cells.  I n addition, GM
-CSF 
is a strong chemo -attractant factor for neutrophils and induces the release of activated 
oxygen species from neutrophils, which can directl y damage cartilage structure [ Dang , 
1999; Gomez -Cambronero, 2003]. Furthermore, it has been demonstrated  pre- clinically   2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
14that GM -CSF is linked to the development of experimental [ Cook , 2012] and 
spontaneous osteoarthritis [ Stone , 2015] and it is associated with pain, function, matrix 
degrading proteases and structural disease severity [ Cook , 2012]. I mportantly , GM -CSF 
neutralization by  a therapeutic monoclonal antibody  rapi[INVESTIGATOR_515246] y abolished 
existing arthritic pain and suppressed the degree of arthritis development in the 
collagenase induced model of OA. 
Taken togethe r, pre -clinical and clinical data suggest that blocking GM -CSF should 
interfere with several pathophy siological pathways and significantly  reduce inflammation 
by [CONTACT_515293] -resident inflammatory  cells, thus leading to a benefit 
on inflammatory  pain and inhibiting bone and cartilage destruction.
2.2.3. [COMPANY_004]3196165
[COMPANY_004]3196165 is a high -affinity  recombinant human monoclonal antibody  (mAb) that 
binds specificall yto human GM -CSF and neutralises its biological function by  [CONTACT_515294] -CSF with its cell surface receptor [ Steidl , 2008]. This results in an 
anti-inflam matory  and anti -nociceptive effect in addition to affecting bone metabolism 
through the Receptor Activator of Nuclear factor -κB ligand (RANKL) pathway  and may  
therefore be a viable treatment option for inflammatory  HOA [ Cook , 2013].
Detailed information relating to non- clinical pharmacology , safet y pharmacology, 
pharmacokinetics and metabolism, toxicology  and other pre -clinical and clinical data 
with [COMPANY_004]3196165 can be found in th e [COMPANY_004]3196165 I nvestigator’s Brochure (IB) and 
supplement [[COMPANY_004] Document Number 2014N190256_00 and [COMPANY_004] Document Number 
2015N226819_00].
2.2.4. Clinical Data
[COMPANY_004]3196165 has been studied in 4 clinical trials to date as summarised in the IB [[COMPANY_004] 
Document Number 2014N190256_00]. I n addition, a Phase IIb, double -blind, placebo 
controlled, dose adaptive study  in 210 subjects with active moderate -severe rheumatoid 
arthritis despi[INVESTIGATOR_515247] [[COMPANY_004] Document Number 
2014N210890_04] has been initiated in several countries. 
MSC -1001 was a Phase1b/2a multi -
center, randomized, sequential group, double- blind, 
placebo- controlled study  which evaluated the sa fety, preliminary  efficacy , and PK of 
multiple doses of [COMPANY_004]3195165 in subjects (N=96) with active, mild-moderate RA 
[Behrens , 2015].  Previous treatment with biological/i mmunosuppressive therapi[INVESTIGATOR_515248] -depleting agents was allowed with an adequate washout period.  Eligible 
patients had active moderate RA (1987 American College of Rheumatology [ACR] RA 
classification criteria, ≥3 swollen and ≥3 tender joints), an elevated C -reactive 
protein (CRP) >5 mg/L (in sero- negative subjects) or CRP >2 mg/L  (in Rheumatoid 
factor [RF] and/or Anti -cyclic citrullinated protein antibody [ACPA] sero- positive 
subjects) and Disease activity  score for 28 different joints (DAS28) sco re ≤5.1.  Subjects 
received 4 IV weekl y doses of [COMPANY_004]3195165 at 0.3 mg/kg, 1.0 mg/kg or 1.5 mg/kg or 
placebo in addition to stable concomitant treatment with Disease modifying 
antirheumatic drugs (DMARDs) or low doses of oral corticosteroids.  Rapid and 
significant reductions in disease activity  (as measured by  [CONTACT_50999]28) were observed with the 
1.0 mg/kg and 1.5 mg/kg doses.  Greater reduction in disease activit y to Week 4 was  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
15observed with 1.0 mg/kg than 1.5 mg/kg in this dose- escalation cohort study .  A 
signif icant reduction in mean DAS28 was not observed in the 0.3 mg/kg group.  Other 
disease activity  measures (e.g., ACR response) and patient -reported outcomes were 
consistent with the results for DAS28.  [COMPANY_004]3196165 was generall y safe and well -
tolerated in this study .  Treatment emergent adverse events (AEs) in the [COMPANY_004]3195165 
groups were mild or moderate in intensit y and generall y reported at frequencies similar to 
those in the placebo group.  I nfections were the most commonly  reported AEs and 
occurred in 26.1% and 29.6% of [COMPANY_004]3196165 and placebo subjects, respectively .  There 
was a numerical imbalance in cough (0/27 placebo, 3/69 active).  There were no apparent 
trends in Pulmonary  function tests (PFTs) or Diffusing capacit y of the lung for carbon 
monoxide (D LCO) changes.  I n two cases, AEs were classified as serious because of 
hospi[INVESTIGATOR_059]: parony chia in a placebo subject and pleurisy  (which responded to 
antibiotics and therefore may  have had an infectious etiology ) in a [COMPANY_004]3195165 0.3 
mg/kg subject.  Both pa tients recovered.
3. OBJECTIVE(S) A ND END POINT(S)
Objectives Endpoints
Primary
To assess the efficacy potential of 
[COMPANY_004]3196165 on pain in inflammatory 
HOA.Change from baseline in 24h average hand pain 
intensity at Week 6, as measured by [CONTACT_515285] (NRS) averaged over the 
7 days prior to assessment visit.
Secondary
To evaluate impact of [COMPANY_004]3196165 
on average and worst HOA pain, over 
time.Change from baseline in 24h average hand pain 
intensity at each visit, measured by [CONTACT_515286] 7 days prior to each 
assessment visit. 
Change from baseline of worst hand pain 
intensity over 24h at each visit, measured by 
[CONTACT_515287] 7 days prior to 
each assessment visit. 
Proportion of subjects in each treatment group 
achieving a 30% reduction in 24h average hand 
pain intensity at each visit, measured by [CONTACT_515288] 7 days prior to 
assessment visit.
Proportion of subjects in each treatment group 
achieving a 50% reduction in 24h average hand 
pain intensity at each visit, measured by [CONTACT_515288] 7 days prior to 
assessment visit. 
Proportion of subjects in each treatment group 
achievin g a 30% reduction in 24h worst hand 
pain intensity at each visit, measured by [CONTACT_515288] 7 days prior to 
assessment visit. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
16Objectives Endpoints
Proportion of subjects in each treatment group 
achieving a 50% reduction in 24h worst hand 
pain intensity at each visit, measured by [CONTACT_515288] 7 days prior to 
assessment visit.
To assess the impact of [COMPANY_004]3196165 
on hand pain (on use), stiffness and 
function, over time.Change from baseline in Australian Canadian 
Hand Osteoarthritis Index (AUSCAN) 3.1 NRS, 
total and domains (pain, morning stiffness, 
function) scores at each visit. 
To assess the impact of [COMPANY_004]3196165 
on HOA inflammation Change in number of swollen and tender hand 
joints at each visit.
To assess potential impact of 
[COMPANY_004]3196165 on disease activity in 
HOA,Change from baseline in patient global 
assessment (PtGA) and physician global 
assessment (PhGA) of disease activity at Week 
6,12 and 22.
To assess safety of [COMPANY_004]3196165 in 
HOA patients, over the study duration.Incidence of adverse events and serious adverse 
events.
Incidence of infections.
Incidence of pulmonary events (cough/dyspnea, 
PAP and D LCO).
Immunogenicity.
To assess population 
pharmacokinetics of [COMPANY_004]3196165 in 
HOA.Population pharmacokinetics endpoints such as 
CL/F, Vss/F, Ka.
Exploratory
To explore the potential impact of 
[COMPANY_004]3196165 on disease 
progression/modification in HOA, 
using MRI imaging.Change from baseline in synovitis in the affected 
hand*, as measured by [CONTACT_1353] -MRI including the 
exchange rate (Ktrans), interstitial volume (v e), 
plasma volume (v p), volume of synovitis, initial 
rate of enhancement (IRE), and maximum signal 
intensity enhancement (ME).
Change from baseline in structural and 
inflammatory HOA features in the affected hand* 
(including synovitis , erosive damage, cysts, 
osteophytes, cartilage space loss, malalignment, 
and  bone marrow lesions) as assessed by [CONTACT_515295]
Change from baseline in structural and 
inflammatory HOA features in the affected hand* 
(including synovitis, bone erosions, joint space 
width, and bone marrow edema) as assessed by 
[CONTACT_515296].
Change from baseline in bone shape as 
assessed by [CONTACT_515297]*.
The exploration of the relationship Relationship between concentration or PK  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
17Objectives Endpoints
between [COMPANY_004]3196165 PK and PD 
effects and/or efficacy.parameters and PD endpoint(s).
To evaluate the potential of 
[COMPANY_004]3196165 to affect biomarkers of 
HOA.Change in blood biomarkers from baseline at 
each visit.
* If only  one hand is affected by [CONTACT_515289], the affected hand 
will be documented at screening and used for all assessments. I n cases where both hands 
are affected b y HOA and both meet the inclusion criteria, then the dominant hand will be 
documented at screen ing and this hand will be used for the MRI assessments throughout 
the study .
4. STUDY DESIGN
4.1. Overall Design
This is a randomized Phase IIa, multicentre, double -blind, placebo -controlled parallel 
group stud y with the primary objective to assess the efficacy po tential of [COMPANY_004]3196165 
on pain, in subjects with active inflammatory  HOA. 
4.2. Stud y Schematic
Approximately  [ADDRESS_667735] 40 subjects will be randomized across the two treatment 
arms, to either placebo or [COMPANY_004]3196165 in a 1:1 ratio (n=20 per arm).  
Thisstudy  will be double -blind (sponsor unblind).  Refer to Section 6.4for details of 
blinding.Primary endpoi nt 
pain at week 6Basel ine pain, function, 
tender  and swollen 
joints, biomar kers, 
safet y and laboratory 
evaluations. Efficacy (pain, 
funct ion, imaging)  and 
safet y at week 125 loadin g doses (Day 1, 8, 15, 22, 29) followed 
by 3 doses every oth er week (D ay 43, 57, 71).
Safet y evaluation, 
MRI and Pain at 
week  22Dosing: [COMPANY_004] 3196165 or Placebo 
(1:1 randomised)
D 43 
(Week 6)
D 85 
(Week 12)
D 155 
(Week 22)D 1
(Week 0)Treatment period
•Pain , function, imaging, PKFollow up period
•Pain , imaging, safetyD 8  
D 15
D 22
D 29
D 57
D 71Screening
Period
•ACR 
classification, 
MRI, Pain, 
tender and 
swollen  joints 
and Safet y 
evalu ationsD -28 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
18For screening, baseline and efficacy assessments, the average pain intensity  over 7 
days prior to assessment date will be used. This is calculated f rom collected daily  
pain NRS data over 7 days.
Imaging MRI will be carried out at screening, Week 12 and Week 22. (Note: MRI  at 
screening will serve as the baseline measurement). 
At baseline subjects will be evaluated by [CONTACT_515298] (average 7 days prior to visit), 
AUSCAN 3.1 NRS, PtGA, PhGA, number of tender and swollen joints in their hands 
and blood will be collected for safety, biomarker monitoring, and pharmacokinetics. 
Througho ut the study  treatment period, subjects will be assessed for hand pain using a 
daily  pain NRS questionnaire (daily  from screening to Week 12). In addition, at the 
specified time points (see Section 7.1, time and events table), function and disease 
state will be assessed using the AUSCAN 3.1 NRS, PtGA and PhGA.  The number of 
tender and swollen joints in affected hands will also be assessed and blood samples 
will be collected for safety, biomarkers monitoring, and pharmacokinetics.
At the Week 22 follow up visit, blood will again be collected for safet y monitoring as 
well an assessment of pain NRS (average 7 days prior to visit), PtGA, PhGA a nd 
MRI  imaging of the affected hand.
For MRI endpoints the assessments are based on one hand onl y.  In cases where both 
hands are affected b y HOA and both meet the inclusion criteria, then the dominant hand 
will be documented at screening and this hand wi ll be used for the MRI assessments 
throughout the stud y.
4.2.1. Pharmacokinetics
The study  will use sparse sampling of [COMPANY_004]3196165 to determine PK parameters and 
associated inter -and intra -subject variability .  The relationship between [COMPANY_004] 3196165
concentrations a nd PD effects and/or efficacy  endpoints will be evaluated if appropriate, 
as an exploratory  endpoint. 
4.2.2. Biomarkers
In addition, a range of exploratory  novel blood biomarkers will be evaluated.  These 
markers will allow confirmation of target engagement and expected pharmacologic 
effects.  These data may  also allow hy potheses to be generated with respect to subgroups 
that are most likely  to benefit from [COMPANY_004]3196165 treatment or earl y on-treatment markers 
that may  predict subsequent response/remission (or lack of response/remission), that may  
guide further development and ultimately  treatment guidelines for prescribers.
4.3. Treatment A rms and Duration
A screening period of up to 4 weeks, will be followed b y a 12 week treatment period 
(dosing with [COMPANY_004]3196165 or place bo) then a follow up period, completing on week 
22. The total study  duration for an individual subject will be approximately 26 weeks.  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
19The Study  consists of 2 arms: treatment with [COMPANY_004]3196165 or placebo will be given 
as a single subcutaneous injection (shi elded to subjects) to the abdomen or thigh, b y 
an unblinded administrator weekl y for 5 injections, from Week 0 to Week 4 (Days 1, 
8, 15, 22, 29), then every other week for 3 further injections, from Week 6 until Week 
10 (Day s 43, 57 and 71).  
In total, ea ch subject will receive up to [ADDRESS_667736] 40 subjects will be randomized
across the two treatment arms, to either placebo or [COMPANY_004]3196165, in a 1:1 ratio (n=20 per 
arm).  
4.5. Design Justification
This study  is designed to investigate whether [COMPANY_004]3196165 may  be a treatment option for 
inflammatory  HOA.
The primary  objective is to demonstrate a reduction in pain at week 6, as indicated b y an 
improvement of at least 2 points in 24h average pain score measured b y pain NRS (0 -10)
for active vs. placebo, which is considered a clinically important difference [Farrar , 2008; 
Salaf fi, 2004 and Farrar , 2001]. I n order to minimise effect of daily  fluctuations in 
patients’ perception of pain, baseline and efficacy  assessments will use a [ADDRESS_667737] on pain would be seen within 
the 6 week timeframe. 
Secondary  endpoints include evaluation of 24h average pain NRS, 24h worse pain NRS 
and responder anal ysis. In addition, hand function, pain on use and stiffness which will 
be assessed b y AUSCAN Hand Osteoarthritis I ndex 3.1 NRS. The AUSCAN Index is a 
self-administered questionnaire that assesses the three dimensions of pain on use, 
function and joint stif fness in hand osteoarthritis using a battery  of 15 questions with 11 -
point (0-10) NRS response options and a 48- hour recall period. The AUSCAN is a valid, 
reliable and responsive measure of outcome and we have chosen the NRS format of the 
AUSCAN in order t o provide consistency  and ease of use for the patient [ Kloppenburg , 
2015; Poole , 2011 and Bellamy , 2002].
Additionally , exploratory MRI  imaging (including Dy namic Contrast Enhanced Magnetic 
Resonance Imagi ng [DCE -MRI ], structural bone shape, the Outcome Measures in 
Rheumatology  Hand Osteoarthritis Magnetic Resonance Imaging Scoring Sy stem 
(OMERACT HOAMRI S) [Haugen , 2014], and the Rheumatoid Arthritis Magnetic 
Resonance Imaging Quantitative Score (RAMRIQ) sy stem [ Bowes , 2014]) will be 
employ ed to explore a potential effect of [COMPANY_004]3196165 on disease modification, which 
includes a reduction in inflammation in terms of synovitis and bone marrow lesions, and 
structural progression in terms of cartilage space loss (as an analog of joint space 
narrowing) and bone shape. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667738] of [COMPANY_004]3196165 on hand function and disease modification, given it is 
unclear how soon these effects could be seen due to the minimal amount of historic data 
in HOA.  A follow up (observational) period, will then take place, completing the stud y 
at Week 22.
The purpose of this stud y is to provide an initial assessment of the therapeutic potential in 
this indication.  Therefore, it is considered appropriate to study  the highest dose possible 
(within safet y margins), so as not to miss potential efficacy within this exploratory stud y. 
Placebo is the most relevant control given the small size of this study  and that drugs are 
not considered to be very effective in this disease state (Non- steroidal anti -inflammatory  
drug [NSAIDs] non- responder) [ Gelber , 2015; Chev alier, 2014; Bijlsma , 2011; Altman, 
2010 and Towheed, 2005]. Secondly  standard of care is variable across different 
countries and hence pi[INVESTIGATOR_515249].  Further given 
the subjective nature of measuring pain response it is important to run this study  in a 
double bl inded fashion.
4.6. Dose Justification
The recommended dosing regimen for this study  includes five loading doses of 180 mg 
SC administered every  week, followed by [CONTACT_102052] 180 mg SC administered 
every  other week.  The predicted PK plasma profile of [COMPANY_004]3196165 at this dose is 
shown i n Figure 1below. This regimen was selected i) to produce sufficient drug 
exposure in both plasma and sy novial fluid to inhibit free GM -CSF and ii) to be 
associated w ith a appropriate margin to the No Observed Adverse Effect Level (NOAEL) 
and the No Effect Level (NOEL) (the dose at which foamy alveolar macrophages were 
not observed in the 13 -week rhesus monkey  study).  Further details are provided below.  
The C min steady-state plasma levels at this dose are predicted to be equal or greater 
than 2 μg/mL , which is the hy pothetical plasma concentration required to bind 
synovial GM- CSF based on in vitro data. Similarly , a mechanistic model, based 
on Pharmacokinetics (PK) characteristics of a t ypi[INVESTIGATOR_226798]1 [ Choy , 2000; Cao , 
2013 and Pejovic , 1995] and GM- CSF binding [ Bell, 1995] predicted at least 90% 
inhibition of free GM -CSF in both plasma and s ynovial fluid. 
The mean steady -state plasma levels predicted at this dose would allow a 26 -fold 
margin to the NOAEL (50 mg/kg), where reversible minimal to mild foamy  
alveolar macrophages (considered non -adverse) were seen in the 26 -week 
monkey  toxicity  study , with a 14-and 3 -
fold margin to the NOEL  dose levels (30 
and 5 mg/kg) identified in the 13 and 26 week monkey toxicity  studies (see Table 
1below). 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
21Table 1 Safety  margins with 180 mg SC [COMPANY_004]3196165 relative to exposures in 
nonclinical toxicology  studies
Study Species Assessment Dose
(mg/kg/wk)AUC (0-336)
µg.hr/mLbFold 
difference
vs. QW
(end of weekly 
dosing phase)Fold difference 
vs. every other 
week dosing
(steady state)
Repeat Dose 
Toxicology,
4 weeks IVRhesus 
MonkeyWeek 45 8814 3.5
NA 25 [ZIP_CODE] 18
100c,d 110201 44
Repeat Dose 
Toxicology,
13 weeks SCCynomolgus 
MonkeyWeek 1310 7124 2.8 3.8
30d [ZIP_CODE] 10 14
100c [ZIP_CODE] 30 40
Repeat Dose 
Toxicology,
26 weeks IVRhesus 
MonkeyWeek 265d 5704 2.3 3.0
15 [ZIP_CODE] 9.0 12
50c [ZIP_CODE] 19 26
MSC -1000 
and 
MOR103C10
4 single dose
(IV & SC)aHumanEnd of weekly 
dosing phase
Days 28 -[ZIP_CODE] mg 
weekly x5
SC2515
Every other 
week at steady 
state
Days 140- 154180 mg 
every other 
week
SC1873
IV intravenous; SC subcutaneous
a. Simulated mean AUC based on analysis of SC and IV data for doses ≥0.5 mg/kg from study MSC1000 (N=18) 
and study MOR103C104 (N=32) with a 2 compartment model and calculation of F by [CONTACT_515299]/ClSCwith 
bioavailability of 44% (95 % CI 37% -53%)
b. As there were no significant differences on sampling occasions or gender differences within each primate study, 
the end of study mean AUC (0 -168) values have been used and multiplied by [ADDRESS_667739] dose level (NOAEL)
d. No observed effect dose level (NOEL)
Figure 1 Predicted [COMPANY_004]3196165 plasma concentrations at the recommended 
dosing regimen (median and 95% confidence interval)
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
224.7. Benefit:Risk A ssessment
Since [COMPANY_004]3196165 is still in early  development with limited efficacy  and safet y data 
available, an integrated Benefit/Risk evaluation has not been performed at this point in 
time. Summa ries of findings from both clinical and non-clinical studies conducted with 
[COMPANY_004]3196165 can be found in the IB and IB supplement [[COMPANY_004] Document Number 
2014N190256_00 and [COMPANY_004] Documen t Number 2015N226819_00].  The following 
section outlines the risk assessment and mitigation strategy  for this protocol:   2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
234.7.1. Risk A ssessment
Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [COMPANY_004]3196165
Infections Immune -modulating biologic drugs (such as anti -Tumor necrosis 
factor [TNF] agents) are associated with an increased risk of 
serious and opportunistic infections.  Similarly, because of the role 
of GM -CSF in anti -infective immunity, [COMPANY_004]3196165 also has the 
potential to increase the risk of infection.
Non-clinical Data:
No changes in peripheral blood populations (lymphocytes, 
neutrophils, monocytes, eosinophils or basophils), phagocytic 
activity of peripheral blood polymorphonuclear cells (investigational 
endpoint in the 26 week study), T -cell dependent response, B- cell 
primary or secondary response, or circulating cytokine levels (26 
week study) were observed.
Studies in knock -out mice showed that GM -CSF deficiency (GM -
CSF-/-) affects the ability of mice to control infection when infected 
with M. tuberculosis or pulmonary group B streptococcus [LeVine , 
1999].
Clinical Data:
One healthy volunteer in study MSC -1000 experienced septic 
shock secondary to pneumonia 29 days after receiving a single 
dose of IP at 1.5 mg/kg.  Subject recovered after treatment with 
antibiotics, and the subject completed the study follow -up period as 
per protocol.
One RA subject in study MSC -[ADDRESS_667740] selection :
Subjects with active infections or a history of recent or 
recurrent infections are not permitted to enter the study.
Subjects with significant leukopenia (white blood cell count 
≤3.0 x109/L) and neutropenia (absolute neutrophil count ≤1.5 x 
109/L) are not permitted to enter the study.
Subjects will be screened for TB, HIV and Hepatitis B and C, 
and excluded from study participation if positive. Subjects with 
any past history of TB or Hepatitis B will also be excluded. 
Investigators ar e expected to assess vaccination status, 
including against influenza and pneumococcus, according to 
local guidelines.
Subject monitoring:
Serious infections are categorised as adverse events of 
special interest (AESIs).
Subjects will be closely monitored f or infections and additional 
information to clarify the events will be recorded in the eCRF. 
Appropriate diagnostic tests will be considered during the 
study if clinically indicated to ensure appropriate safety 
monitoring.
Subjects will be instructed as to the signs and symptoms of 
infection, and to contact [CONTACT_515300].  
This information will also be contained within the patient 
Informed Consent Form.
Withdrawal criteria:
In the event of a serious infection, study medication should be  
 
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
24Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
discontinued and the subject withdrawn from the study.
Pulmonary alveolar 
proteinosis (PAP)GM-CSF signalling is required to maintain the normal function of 
alveolar macrophages.  Long -term a bsence of GM -CSF signalling 
(e.g., via hereditary GM -CSF deficiency or development of anti -
GM-CSF auto -antibodies) is known to cause the extremely rare 
condition of PAP, which is characterized by [CONTACT_515301][INVESTIGATOR_515250], with resultant 
impairment in gas exchange.
Non-clinical Data:
Non-adverse minimal to mild foamy alveolar macrophage 
accumulation were noted in lungs of monkeys in the 13 -week SC 
and 26 -week IV toxicology studies, but reversible following off drug 
period.  Dose levels at which foamy alveolar macrophages were 
not observed were identified in these studies.
Clinical Data:
No cases of PAP have been reported to date in the clinical 
development program .  Furthermore evaluation of pulmonary 
function h as not demonstrated any abnormalities in pulmonary 
functions.Subject selection 
Subjects with history of clinically -significant respi[INVESTIGATOR_515251]/or follow up, or chronic 
cough or dyspnea will not be permitted to enter the study.
Pulmonary function testing (spi[INVESTIGATOR_038], D LCO) will be performed 
at baseline in order to exclude those subjects with impairment. 
Subjects with abnormal D LCOor Forced expi[INVESTIGATOR_515252] (FEV1) will be excluded. 
Dose Duration:
The exposu re duration to [COMPANY_004]3196165 in this study is 3 
months.  Although the time course of Pulmonary alveolar 
proteinosis (PAP) development in humans is unknown, the 
published literature suggests that it requires full inhibition of 
GM-CSF for years before clinical manifestation of the disease 
can be detected (refer to IB [COMPANY_004] Document Number 
2014N190256_00 for further details).  Therefore, the risk of 
development of PAP in this study is anticipated to be low.
Subject Monitoring:
Specific pulmonary assessments are a requirement of the 
study protocol:
oSubjects will be assessed every visit for the 
development of cough and dyspnea, and will also 
have regular chest auscultation and pulse oximetry 
measurements.  Persistent cough or dyspnea will be 
reported as an AESI.
oPulmonary function testing (spi[INVESTIGATOR_10230] D LCO
measurements) will be performed at baseline, and 
then at week 12 and at the follow -up visit.  Relative 
change in D LCO>15%  from baseline will be reported  
 
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
25Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
as an AESI if confirmed with three consecutive 
weekly tests.
 In the event of any new or clini cally significant pulmonary 
abnormalities that may develop during the study and 
persist for three consecutive weeks (e.g., increased 
shortness of breath/dyspnea, or unexplained and 
persistent coughing; or >15% relative decrease in D LCO
from baseline), the subject will be withdrawn from study 
drug for the remainder of the study and it is recommended 
that the subject be referred to a pulmonologist for further 
assessment [Section 5.5.1 ]. The subject should be 
followed until the symptoms or signs that caused referral 
have resolved and/or the diagnosis has been determined.  
Suggested pulmonary assessment and management 
algorithms are provided in Appendix 6 .
Hypersensitivity reactions, 
including anaphylaxisThere is a potential risk of hypersensitivity reactions, including 
anaphylaxis, during and following the administration of protein -
based products, such as [COMPANY_004]3196165.
Clinical Data:
No allergic or acute systemic reactions have been observed to date 
in the clinical development program.Subject selection 
Subjects with a history of sensitivity to any of the study 
treatments, or components thereof, or a history of drug or other 
allergy that, in the opi[INVESTIGATOR_427175], contraindicates their participation, will not be 
permitted to enter the study.
Study treatment administration/Subject monitoring:
All SC administrations will be performed at the clinical site.
Subjects will be required to remain monitored at the site for [ADDRESS_667741] 3 injections, and then for 30 
minutes for subsequent injections.
Subjects should be informed of the signs and symptoms of an 
acute hypersensitivity reaction, and be instructed to seek 
immediate medical care should they develop.  This information 
will also be contained within the patient Informed Consent  
 
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
26Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Form.
Should hyp ersensitivity or anaphylaxis occur, subjects should 
be managed appropriately per local guidelines/medical 
judgement.
Severe or serious hypersensitivity or anaphylaxis are 
categorised as AESIs.
Subject monitoring:
Subjects should be monitored for hypersensitivity reactions 
throughout the study, and the information recorded in the 
eCRF.
Any clinically -significant event should be reported as an AE.
Withdrawal criteria:
In the event of severe or serious hypersensitivity or 
anaphylaxis, study medicatio n should be discontinued and the 
subject withdrawn from the study.
Injection site reactions SC injections may be associated with local reactions ( e.g., swelling, 
induration, pain).
Non-clinical & Clinical Data:
No macroscopic or microscopic changes indicative of local injection 
site reactions were observed following IV or SC administration.Subject monitoring:
Subjects should be monitored for injection site reactions 
throughout the study, and the information recorded in the 
eCRF.
Injection sites will be rotated.
Any clinically -significant event should be reported as an AE.
Immunogenicity Pre-clinical Data
Anti-drug antibodies (ADAs) to [COMPANY_004]3196165 were detected in 
some monkeys and was associated with reduced serum levels of 
[COMPANY_004]3196165; ADA associated toxicity was not observed. 
Clinical Data
In Study MSC1000, one healthy volunteer who received a single 
dose of 25 µg/kg developed an IgM ADA at Day 15, and in Study Investigate Risk
Samples (pre -and post -baseline) will be collected from all 
subjects during the study to assess development of anti 
drug antibodies and will be analyzed at the end of the 
study. 
In addition to scheduled immunogenicity assessments, 
“event- driven” testing will also be employed for those 
subjects that experience anaphylaxis, serious  
 
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
27Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
MSC1001 one RA subject who received 4 weekly doses of 1.0 
mg/kg dose developed an IgG ADA at Week 13, but not at Week 
16 (with no impact on [COMPANY_004]3196165 serum concentration).hypersensitivity or adverse events that are deemed to be 
clinically significant in the opi[INVESTIGATOR_871], and 
related to study drug administration that lead to withdrawal 
from the study, blood samples will be taken for 
immunogenicity testing at the time of the event and again 
[ADDRESS_667742] maturation of leukocytes and their precursors, 
mice lacking GM -CSF do not develop neutropenia or show any 
major perturbation of hematopoiesis [ Stanley , 1994].
Non-clinical & Clinical Data:
There have been no reports of neutropenia or decreases in 
leukocytes in the non -clinical and clinical [COMPANY_004]3196165 program.Subject selection 
Subjects with significant leukopenia (WBC ≤3.0 x 109/L); 
thrombocytopenia (platelet count ≤100 x 109/L); neutropenia 
(absolute neutrophil count ≤1.5 x 109/L);lymphocytopenia 
(≤0.8 x 109/L) within [ADDRESS_667743] monitoring:
A full blood count (with differential) will be performed at regular 
intervals throughout the study (ref. Time and Events Table,).
Grade 3 or 4 neutropenia will be reported as an AESI.
Reproductive toxicity Published studies performed with GM -CSF -/-mice have indicated 
that GM -CSF depletion potentially affects fertility, establishment of 
pregnancy and post partum development of offspring in the mouse.
Non-clinical Data:
No [COMPANY_004]3196165 -related effects on female or male fertility were 
noted in the SC 13 -week repeat dose monkey study at doses up to 
100 mg/kg/week (highest dose tested).  In addition no maternal, 
embryofoetal or effects on fertility were noted in the reproductive 
toxicology studies using the surrogate rat anti -mouse GM -CSF 
monoclonal antibody, 22E9.
The effect on human pregnancy is unknown.Subject selection 
Male and female subjects will only be permitted to enter the 
study if they meet the contraception requirements detailed in 
inclusion criterion 
In addition, females of child bearing pote ntial will undergo 
pregnancy testing at screening and at regular intervals during 
the study (ref. Time and Events Table, Section 7.1).
Withdrawal criteria:
In the event of a pregnancy in a female subject in the study, 
study medication should be discontinued and the subject 
withdrawn from the study. 
 
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
28Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Clinical Data:
No HVs or RA subjects became pregnant during the studies, but 
one MS subject was found to be pregnant during study 
MOR103C10301028 and received four 2.0 mg/kg doses, the 
pregnancy was terminated 2 weeks later by [CONTACT_515302].Other considerations
Female subjects who become pregnant will be followed to 
determine the outcome of the preg nancy. If a female partner of 
a male subject becomes pregnant, they will be followed to 
determine the outcome of the pregnancy.
Any pregnancy complication or elective termination of a 
pregnancy will be reported as an AE or SAE.
Malignancy Immunomodulatory therapi[INVESTIGATOR_515253].
Non-clinical & Clinical Data:
There have been no reports of malignancy in the non -clinical and 
clinical [COMPANY_004]3196165 program.Subject selection 
Subjects with a history of malignant neoplasm within the last 
10years or breast cancer within the last [ADDRESS_667744] Selection:
All participants will be screened according to local hospi[INVESTIGATOR_515254]/exclusion before entering the MRI room to 
ensure they are able to have the MRI conducted. Subjects with 
non-MR compatible metal implants or implantable electronic 
devices (e.g. pacemaker, defibrillator) will not be included in this 
study.
Gadolinium (Gd) 
containing MRI contrast 
agentsNon-clinical data:
Animal studies have shown reproductive toxicity of gadolinium -
containing MRI contrast agents at repeated high doses.
Clinical data:
Use of MRI contrast agents in subjects with severely impaired renal Subject Selection:
Pregnant or breast feeding females will be excluded from 
taking part in the study.  
Subjects with impaired renal function (GFR<60ml/minute) are 
excluded by [CONTACT_99099].  
Subjects with history of sensitivity to Gd -containing contrast 
agents will be excluded from the study. The MRI procedure will  
 
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
29Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
function (Glomerular filtration rate [GFR]<30ml/minute) has been 
associated with Nephrogenic Systemic Fibrosis (NSF).  In subjects 
with severely impaired renal function, the benefits of the use of 
contrast agents should be carefully weighed against the risks.
Gd contrast agents can be associated with 
anaphylactoid/ hypersensitivity or other idiosyncratic reactions, 
characterized by [CONTACT_515303], respi[INVESTIGATOR_515255], and ranging to severe reactions including shock. In 
general, subjects with cardiovascular disease are more susceptible 
to serious o r even fatal outcomes of severe hypersensitivity 
reactions.
The risk of hypersensitivity reactions may be higher in case of:
previous reaction to contrast media
history of bronchial asthma
history of allergic disorders
Most of these reactions occur within half an hour of administration. 
Delayed reactions (after hours or several days) have been rarely 
observed.be conducted under the supervision of a trained and qualified 
clinical st aff who are trained to appropriately manage an 
allergic reaction.
Sites will be responsible for following any additional safety 
information for the specific gadolinium contrast agent used at 
their site and not enrol subjects if contraindicated.
Subject mo nitoring and management:
MRI contrast at a dose less than or equal to 0.1 mmol/kg will 
be used in the MRI protocol.
Effective contraception is required during the study, and pregnancy 
tests will be performed regularly throughout the study prior to 
dosing i n females of child bearing potential. 
 
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
304.7.2. Benefit A ssessment
Pain associated with HOA does not respond well to current analgesic treatments [ Gelber , 
2015; Chevalier , 2014; Bijlsma , 2011; Altman, 2010 and Towheed, 2005]. Thus subjects 
entering the stud y, who receive active drug, have the potential to receive benefit over 12 
weeks of treatment.
Participation in this study will contribute to the evaluation of a potential new therap y in 
an area of high unmet need.
4.7.3. Overall Benefit:Risk Conclusion
[COMPANY_004]3196165 is a high -affinity  recombinant monoclonal antibody  (mAb), IgG1 lambda, 
that binds specificall y to human GM -CSF and neutralises its biological function resulting 
in an anti -inflammatory  and anti -nociceptive effect in addition to affecting bone 
metabolism thro ugh the RANKL  pathway  and may  therefore be a viable treatment option 
in osteoarthritis
Key potential risks are those described above that may  be associated with inhibition of 
GM-CSF ( e.g., pulmonary  toxicity , infection) and those associated with administration of 
a therapeutic monoclonal antibody  (e.g. allergic reactions).  Robust and sy stematic safet y 
monitoring will be undertaken in studies of [COMPANY_004]3196165 to proactivel y address and 
mitigate the potential risks.  
Given the safety  monitoring that has been put in place to minimiz e risk to subjects 
participating in clinical studies of [COMPANY_004]3196165 , the potential risks identified are justified 
by [CONTACT_515304] .
5. SELECTION OF STUDY P OPULA TION A ND 
WITHDRA WAL CRITERIA
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the [COMPANY_004] investigational product or other study  
treatment that may  impact subject eligibility  is provided in the IB [[COMPANY_004] Document 
Number 2014N190256_00] and IB supplement [[COMPANY_004] Document Number 
2015N226819_00].
Deviations fr om inclusion and exclusion criteria are not allowed because they  can 
potentially  jeopardize the scientific integrity  of the study , regulatory  acceptability  or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential. 
In addition, investigators are expected to assess vaccination status, including against 
influenza and pneumococcus according to local guidelines. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667745] will be eligible for inclusion in this study onl y if allof the following criteria
apply :
AGE
1.Age ≥ [ADDRESS_667746] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY 
2. Meets ACR classification of OA and isintolerant to,or hasnot responded to 
analgesics (level 1 and 2) or to NSAIDs for at least [ADDRESS_667747] two swollen and tender PIP and/or DIP 
joints in the affected hand* .
4.Signs of inflammation such as s ynovitis in the MRI scan of the affected hand*.
5.Must have a patient’s self assessment of 24h average hand pain intensity  of at least 
‘5’ on an 11- point NRS (0 -10), calculated as an average using data from the 7 day s 
prior to assessment date.
*If only  one hand is affected by  [CONTACT_515289], the affected hand
will be documented at screening and used for all assessments. I n cases where both hands 
are affected b y HOA and both meet the inclusion criteria, then the dominant hand will be 
documented at screening and this hand will be used for the MRI assessments thr oughout 
the study .
WEI GHT
6.Body weight 45 kg.
SEX
7.Male or female subjects are eligible to participate so long as they  meet and agree to 
abide b y the contraceptive criteria detailed in Appendix 5 .
INFORMED CONSENT
8.Written informed consent prior to any  of the screening procedures including 
discontinuation of prohibited medications.
OTHER SAFETY -RELATED
9.Diffusing capacity  of the lung for carbon monoxide (D LCO ) ≥ 70 % predicted and 
forced expi[INVESTIGATOR_4034] 1 second (FEV1) ≥ 80 % predicted.
10. No evidence of active or latent infection with Mycobacterium tuberculosis (TB), as 
defined by [CONTACT_3959]:
a.No history  of active or latent TB infection irrespective of treatment status. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667748] within 28 day s of baseline (Day  1) defined as: a 
negative QuantiFERON Gold test or T- spot test (may  be performed locally ) (NB: 2 
successive indeterminate QuantiFERON tests will be considered as a positive 
result).
Note: If there has been recent close contact [CONTACT_515305] a TB phy sician to undergo additional 
evaluation.
5.2. Exclusion Criteria
A subject will no t be eligible for inclusion in this study  if any of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AND QTc INTERVAL) 
1. Pregnant or lactating females.
2.Significant unstable or uncontrolled acute or chronic disease ( e.g., cardiovascular 
including uncompensated congestive cardiac failure NYHA III or IV, m yocardial 
infarction within 12 months, unstable angina pectoris, uncontrolled hy pertension, 
hypercholesterolemia) pulmonary , hematologic, gastrointestinal (in cluding Crohn’s
Disease orulcerative colitis) , hepatic, renal, neurological, psy chiatric, malignancy , 
endocrinological, immunologic or infectious diseases, which, in the opi[INVESTIGATOR_1070], could confound the results of the study  or put the subje ct at undue risk.
3.History  of any  clinicall y significant inflammatory  disease other than inflammatory  
HOA, especiall y, but not limited to, rheumatoid arthritis or spondylarthropathies.
4.Diagnosis of rheumatoid arthritis, fibromy algia, gout, calcium py rophosp hate 
deposition disease C[COMPANY_003], pseudogout, hemochromatosis or other inflammatory  
rheumatological or autoimmune disorders.
5.Clinical suspi[INVESTIGATOR_1884], or previous investigation for C[COMPANY_003] or pseudogout, or history  of 
chondrocalcinosis.
6.Any injury , medical or surgic al procedure to the affected joint(s) that may  interfere 
with evaluation of the target HOA joint(s).
7.History ofanyclinicall y-significant respi[INVESTIGATOR_515256]/or
follow upunder thedirection of aphysician oranyrespi[INVESTIGATOR_515257] I nvestigator would compromise the ability  of the subject to complete 
the study (e.g.interstitial lung disease, such aspulmonary fibrosis, chronic
obstructive pulmonary disease [COPD], moderate -severe asthma, bronchiectasis,
pneumonitis, pulmonary alveolar proteinosis (PAP), significant exposure to
pneumotoxins (e.g.inhaled silica).
8.Clinically -significant orunstable (intheopi[INVESTIGATOR_317584]) persistent cough
ordyspnea thatisunexplained .
9.QTc > 450 msec or QTc > 480 msec in subjects with Bundle Branch Block based on 
averaged values of triplicate electrocardiograms obtained over a brief (e.g. 5 -10 
minute) recording period
The QTc is the QT interval corrected for heart rate according to Bazett’s formula 
(QTcB) , Fridericia’s formula (QTcF), and/or another method, machine -read or  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
33manually  over -read.
10.ALT >2xUL N and bilirubin >1.5xUL N (isolated bilirubin >1.5xUL N is acceptable if 
bilirubin is fractionated and direct bilirubin <35%). 
11.Current or chronic history of l iver disease, or known hepatic or biliary  abnormalities 
(with the exception of Gilbert's s yndrome or as ymptomatic gallstones)
12.A history  of malignant neoplasm within the last [ADDRESS_667749] been excised and cured 
or carcinoma in situ of the uterine cervix. 
13.Kidney  disease : Current or history  of renal disease, or estimated creatinine clearance 
<60 mL /min/1.73m2or serum creatinine >1.5xULN within [ADDRESS_667750] 
infections.
16.Active infections, or history  of recurrent infections (excluding recurrent fungal 
infections of the nail bed), or have required management of acute or chronic 
infections, as follows: 
a.Currently  on any  suppressive therap y for a chronic inf ection (such as tuberculosis, 
pneumocy stis, cy tomegalovirus, herpes simplex virus, herpes zoster and at ypi[INVESTIGATOR_356539]).
OR
b.Hospi[INVESTIGATOR_53039] 26 weeks of Day  1.
OR
c.Use of parenteral (IV or IM) antimicrobials (antibacteri als, antivirals, antifungals, 
or antiparasitic agents) within 26 weeks of Day  1 or oral antimicrobials within 14 
days of Day  1.
17.A vaccination (live or attenuated) within [ADDRESS_667751] anned during the course of the study .
18.Any surgical procedure, including bone or joint surgery /synovectom y within 12 
weeks prior to Day  1 or any  planned surgery  within the duration of the study  or 
follow -up period.
19.Contraindication to MRI  scanning (as assessed by  [CONTACT_515306] y questionnaire) 
which includes but not limited to:
a.Intracranial aneury sm clips (except Sugita) or other metallic objects,
b.History  of intra -orbital metal fragments that have not been removed by  [CONTACT_515307],
c.Pacemakers or other implanted cardiac rh ythm management devices and non -
MR compatible heart valves,
d.Inner ear implants, except MR -conditional implants scanned within 
manufacturer guidelines ,
e.History  of claustrophobia which may  impact participation 2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667752] be 
discontinued for the stated time in Section 6.10.2 prior to Day  1.
Note: For patients who need to discontinue prohibited medication > [ADDRESS_667753] negative titer rheumatoid factor (RF) and anti- CCP antibody .
25.Any Grade 3 or 4 hematology  or clinical chemistry  laboratory  abnormality  [CTCAE , 
2009 v4.0] within 28 day s of Day  1.
26.Hemoglobin ≤9 g/dL; white blood cell count ≤3.0 x109/L; platelet count ≤100 X 
109/L; absolute neutrophil count ≤1.5 x 109/L;lymphoc yte count ≤0.8 x 109/L within 
28 day s of Day  1.
27.Presence of hepatitis B surface antigen (HBsAg) and/or presence of hepatitis B core 
antibody  (HBcAb) at screening.
28.Positive hepatitis C antibody  test result at screening. Subjects with positive Hepatitis 
C antibody  due to prior resolved disease can be enrolled only  if a confirmatory  
negative Hepatitis C RNA PCR test is obtained.
29.Positive serology  for human immunodeficiency  virus (HIV) 1 or 2 (within 28 day s of 
Day 1).
30.A positive pre -study  drug/alcohol screen.
31. The subject has participated in a clinical trial and has received an investigational 
product within the following time period prior to the first dosing day  in the current 
study : [ADDRESS_667754] (whichever is longer).
32.
Exposure to more than [ADDRESS_667755] dosing day . 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
355.3. Screening/Baseline/Run-in Failures
Screen failures are defined as subjects who consent to participate i n the clinical trial but 
are never subsequently  randomized. In order to ensure transparent reporting of screen 
failure subjects, meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements, and respond to queries from Regulatory authorities, a minimal 
set of screen failure information is required including Demograph y, Screen Failure 
details, Eligibility  Criteria, and Serious Adverse Events (see Section [IP_ADDRESS] ).
5.3.1. Re-Screening
If a subject has not met all the eligibility  criteria within the 28 day  screening period, re-
screening is required.  Subjects are onl y allowed to be re- screened once; the entire 
screening process must be repeated.
If a blood sample has to be withdrawn due to sample handling problems, breakage or 
sample integrity , this is not considered a re- screening.
Further details regarding the procedure for re -screening may be found in the Study  
Reference Manual (SRM).
5.3.2. Re-Testing –Laboratory  Exclusion
If a subject fails an y of the laboratory exclusion criteria, the test may be repeated twice 
within the screening period.  If the subject fails the laboratory  criteria for a third time 
they will be considered a screen fail ure; these subjects may  be re -screened as described in 
Section 
5.3.1.
If a blood sample has to be withdrawn due to sample handling problems, breakag e or 
sample integrity , this is not considered a re- testing.
Further details regarding the procedure for re -testing may  be found in the SRM.
5.4. Withdrawal/Stoppi[INVESTIGATOR_428111] a subject who fails to attend the cl inic 
for a required stud y visit:
The site must attempt to contact [CONTACT_131993]- schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_667756]’s last 
known mailing address or local equivalent methods). These contact [CONTACT_131994]’s medical record.  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
36Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
A subject may  withdraw from study  treatment at any  time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioural or
administrative reasons. 
In addition, study medications will be discontinued and the subject withdrawn from 
the study in the event of any of the following:
All serious infections. 
Pregnancy .
Confirmed PAP
Severe or serious h ypersensitivity  reactions, including anaph ylaxis.
If the liver chemistry  stoppi[INVESTIGATOR_3418] (Section 5.4.1) or QTc stoppi[INVESTIGATOR_3418] 
(Section 5.4.2) are met.
Other serious or severe adverse events, at the discretion of the Investigator, after 
consultation with the [COMPANY_004] Medical Monitor.
Persistent or recurrent hematologic laboratory  abnormalities (see Sec tion 5.5.2 ).
If a subject withdraws from the study , he/she may request destruction of any  samples 
taken, and the investigator must document this in the site study  records . In each case the 
reason for withdrawal will be recorded in the eCRF.
A subject that is withdrawn earl y from the study after being randomized to treatment 
cannot be re -screened, but should be encouraged to return for the Earl y Withdr awal visit.
5.4.1. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in alignment with the FDA 
premarketing clinical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
37Phase II Liver Chemistry Stoppi[INVESTIGATOR_515258] y Required Actions and Follow up Assessments Section can be found in 
Appendix 2 .
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_515259].
5.4.2. QTc Stoppi[INVESTIGATOR_2121]
The same QT correction formula must be used for each individual subject to 
determine eligibility  for and discontinuation from the study .  This formula may  
not be changed or substituted once the subject has been enrolled.
For example, if a subject is eligible for the protocol based on QTcB, then QTcB 
must be used for discontinuation of this individual subject as well.
Once the QT correction formula has been chosen for a subject’s eligibility , the 
same formula must continue to be used for that subject for all QTc data being 
collected for data analysis .  Safety  Electrocardiogram (ECGs) and other non -
protocol specified ECGs are an exception.  
The QTc should be based on averaged QTc values of triplicate electrocardiog rams 
obtained over a brief (e.g. 5- 10 minute) recording period.  Continue  Study  Treatmen t 
Discontinue  Study  Treatmen t Plus
Bilirubin≥2x
ULN (>35% 
direct) 
or plus
INR>1.5, if 
measur ed*
Possi ble
Hy’s LawALT≥3xULNALT≥5xULNALT≥3xULN
Plus
Sympt oms of 
liver injury
or 
hyper sensitivityALT≥3xULN
but able to 
moni tor 
week ly for 
4 week sNo
Yes
YesYes YesNo No No
NoYes
ALT≥3xULN
persist for
4 week s or 
stoppi[INVESTIGATOR_278786]
*INR value not applicable to subjects on  anticoagu lantsYesIf subj ect to be monitor ed weekl y must refer to Liver Safety Requi red  Actions and  Follow  up 
Assessm ents  section  in  the  Appendi x
Must refer to Liver Safety Requi red Actions and Follow  up Assess ments section in the Appendi x
Repor t as an SAE if possible Hy’s Law case:  ALT≥3xUL N and  Bilirub in≥2xULN (>35% direct)  or 
INR>1.5, if measur ed* 2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667757] who meets either of the bulleted criteria below will be withdrawn from the 
study :
QTc > 500 msec OR Uncorrected QT > 600 msec
Change from baseline of QTc > 60 msec
For patients with underl ying bundle branch block , follow the discontinuation criteria 
listed below:
Baseline QTc with Bundle Branch Block Discontinuation QTc with Bundle 
Branch Block
< 450 msec > 500 msec
450 – 480 msec ≥ 530 msec
5.5. Treatment withdrawal
Subjects will be permanently  withdrawn from study  treatment if any  of the following 
respi[INVESTIGATOR_515260], investigation will be carried 
out as described below. After withdrawal of treatment under these conditions, wher e 
possible subjects should remain in the study  (off treatment) in order to complete all 
remaining visits/assessments.
5.5.1. Respi[INVESTIGATOR_515261]:
Persistent reduction in D LCO >15% relative decrease from baseline for three 
consecutive weeks 
Persistent cough (Common terminology  criteria [CTC] grade 2 or 3, see Appendix 7 ) 
for three consecutive weeks
Persistent dy spnea (Borg CR10 scale grade 3 or above, see SRM) for three 
consecutive weeks.
Upon an y of these persistent symptoms, it is recommended that the subject be referred to 
a pulmonologist for further assessment .  The subject should be followed until the 
symptoms or signs that caused referral have resolved and/or the diagnosis has been 
determined. Suggested pulmonary  assessment and management a lgorithms are provided 
in Appendix 6 .
5.5.2. Hematologic abnormalities
The following hematological laboratory  abnormalities require withdrawal of study  
medications for the remainder of the study and prompt retesting, ideally  within 3 -5 day s: 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
39White blood cell count < 2.0 x 109/L
Absolute neutrophil count < 1.0 x 109/L
Lym phocy te count <0.5 x 109/L
Subjects should be followed as appropriate until resolution of the event. Absolute 
neutrophil count <1.0 x 109/L(Grade 3 or greater) should be reported as an AE. 
5.6. Subject and Study  Completion
A completed subject is one who has completed all phases of the s tudy including the 
follow -up visit.
The end of the stud y is defined as the last subject’s last visit.
6. STUDY TREA TMENT
Treatment with [COMPANY_004]3196165 will be given as a single subcutaneous injection to the 
abdomen or thigh, b y an unblinded administrator (shielde d to subjects).
6.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to describe an y combination 
of products received b y the subject as per the protocol design. Stud y treatment may 
therefore refer to the individual study  treatments or the combination of those study  
treatments.
Study Treatment
Product name: [CONTACT_23983]3196165 Placebo
Function Test (investigational product) Control
Formulation description: See IB [[COMPANY_004] Document 
Number 2014N190256_00 ] for 
details.The placebo in this study will 
be sterile 0.9% (w/v) sodium 
chloride solution.
Dosage form: Liquid Liquid
Dosage levels (volumes): 180 mg (1.2mL) 1.2 mL
Route of Administration: Investigational product should be administered SC into thigh or 
abdomen, sites should be rotated.  Safety should be monitored 
for [ADDRESS_667758] 3 injections, then for 30 
minutes thereafter.  Such monitoring will include general safety 
monitoring including monitoring for systemic hypersensitivity 
infusion reactions and local injection site reactions.  Trained 
rescue personnel and rescue medications/equipment must be 
available for use at all times. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
40Study Treatment
Dosing instructions: [COMPANY_004]3196165/placebo should be administered on the same day 
each week ± [ADDRESS_667759] 5 weekly doses (with a minimum 
of 5 days between doses, for no more than 2 consecutive doses).  
Following this [COMPANY_004]3196165/placebo should be administered on 
the same day every other week ± 3 days (with a minimum of 8 
days between doses).
[COMPANY_004]3196165/placebo will be discontinued as described in 
Section 5.4andSection 5.5.
Subjects will be randomized as shown in Time and Events Table, 
Section 7.1, and the dosing schedule should be followed as 
closely as possible.
The unblinded administrator (study co -ordinator or nurse) 
assigned to the study will be required to prepare and administer 
the appropriate medication according to the study subject’s 
treatment assignment.  Subjects eligible to enter the study will be 
assigned to treatment randomly through an Interactive Response 
Technology System (IRTS).  Procedures must be in place to 
ensure the blind is maintained by [CONTACT_515308] a ssessment of the subject, and by [CONTACT_515309]. Further details are provided in the SRM.
Every attempt should be made to ensure all doses are 
administered.
If at any time the subject misses a dose, the Medical Monitor 
must be contact[CONTACT_515310].
Physical description: Sterile, aqueous solution of 
purified monoclonal antibody 
150 mg/mLSterile 0.9% (w/v) sodium 
chloride solution.
Method for individualizing 
dosage:180 mg (1.2 mL) dose will be 
drawn into a small ( e.g. 2 or 3 
mL) syringe and should be 
dosed immediately.A volume of 1.2 mL will be 
drawn into a small ( e.g. 2 or 3 
mL) syringe and should be 
dosed immediately.
6.2. Treatment A ssignment
Subjects will be assigned to study  treatment in accordance with the rando mization 
schedule.
The study  will use central randomization and the randomization schedule will be 
generated b y Clinical Statistics, prior to the start of the study, using validated internal 
software.  Once a randomization number has been assigned to a sub ject, it cannot be 
assigned to another subject in the study , even if the original subject withdraws before 
taking stud y medication.
Randomization numbers will be assigned to subjects using an Interactive Response 
Technology  System (I RTS). I nformation and t elephone numbers for the IRTS will be 
provided in the SRM. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667760] dose of study  medications on the 
same day  (Day  1).
6.3. Planned Dose A djustments
This protocol uses a fixed dose and no alteration to this dose leve l is allowed.
6.4. Blinding
The study  will be double -blind (sponsor unblind), which means that the subject, 
investigator and trial staff at site (apart from unblinded administrator(s) and pharmacy  
staff), will be blinded to the trial treatment allocated to each individual subject. In 
addition, the sponsor central and local stud y teams will be blinded to treatment 
allocations, except for roles required to be ‘unblind’ in order to manage study  conduct 
and oversight (including unblinded monitor(s)) and roles specif ied in the Reporting and 
Analy sis Plan ( RAP )as involved with the preparation and review of the planned interim 
analyses.
The RAP , which will be approved prior to the first unblinding, will identify the specific 
[COMPANY_004] individuals involved; outline in detail the activities of the interim analyses, and how 
the integrit y of the study will be maintained.
At sites, t here will be a t least one unblinded administrator (study  co-ordinator or nurse)
who will prepare and administer the study  treatment.
In the case of emergency unblinding (eg. through RAMOS NG or [COMPANY_004] Clinical support 
help desk), the following will apply :
The investigator or treating ph ysician may  unblind a subject’s treatment 
assignment only in the case of an emergency OR in the event of a serious 
medical condition when knowledge of the stud y treatment is essential for the 
appropriate clinical management or welfare of the subject as judged b y the 
investigator. 
Investigators have direct access to the subject’s individua l study  treatment. 
It is preferred (but not required) that the investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  personnel to discuss options before unblinding 
the subject’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_222201], the investigator must 
notify  [COMPANY_004] as soon as possible after unblinding, but without revealing the 
treatment assignment of the unblinded subject, unless that information is 
important for the safety  of subjects currently  in the study . 
The date and reason for the unblinding must be fully  documented in the eCRF 
A subject will be withdrawn if the subject’s treatment code is unblinded b y the 
investigator or treating phy sician. The primary  reason for discontinuation (the event or 
condition which led to the unblinding) will be recorded in the eCRF. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
42[COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may unblind 
the treatment assignment for an y subject with an SAE. If the SAE requires that an 
expedited regulatory  report be sent to one or more regulatory  agencies, a copy  of 
the report, identify ing the subject’s treatment assignment, may  be sent to 
investigators in accordance with local regulations and/or [COMPANY_004] policy .
6.5. Packaging and Labelling
The contents of the label for [COMPANY_004]3196165 and placebo will be in accordance with all 
applicable regulatory  requirements for clinical supplies.
6.6. Preparation/Handling/Storage/A ccountability
No special preparation of study  treatment is required.
Only  subjects enrolled in the study  may  receive study  treat ment and onl y 
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must be stored in a secure environmentally  controlled and monitored 
(manual or automated) area in accordance with the labelled storage conditions 
with acces s limited to the investigator and authorized site staff. 
The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  treatment accountability , reconciliation, and 
record maintenance (i.e. receipt, reco nciliation and final disposition records).  
Further guidance and information for final disposition of unused study  treatment 
are provided in the SRM. 
Under normal conditions of handling and administration, study  treatment is not 
expected to pose signific ant safet y risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_23968]. In the case 
of unintentional occupational exposure notify the monitor, Medical Monitor 
and/or [COMPANY_004] study  contact.
A Mater ial Safety  Data Sheet (MSDS)/equivalent document describing 
occupational hazards and recommended handling precautions either will be 
provided to the investigator, where this is required by [CONTACT_1207], or is available 
upon request from [COMPANY_004].
6.7. Compliance with Stud y Treatment A dministration
[COMPANY_004]3196165 or placebo will be administered b y subcutaneous injection to subjects at the 
siteby [CONTACT_515311] (study  co-ordinator or nurse) .  The date and time of 
each dose and volume administered in the clinic will be recorded in the eCRF.
6.8. Treatment of Study  Treatment Overdose
6.8.1. Overdose of [COMPANY_004]3196165
There is very  limited clinical safet y data at this stage of development.  However there 
have been no reports of overdose with [COMPANY_004]3196165 to date.  The risk of overdo se  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
43occurring is considered low because [COMPANY_004]3196165 will be administered by [CONTACT_515312], and the maximum volume that can be withdrawn from the vial 
is equivalent dose to be evaluated (1.2 mL) .  No specific treatment is recommended for 
an ove rdose of [COMPANY_004]3196165, and the investigator should treat as clinicall y indicated.  
Details (amount of investigational product given and any  resulting AEs/SAEs) should be 
recorded in the eCRF.
In the event of an overdose the investigator should:
1.contact [CONTACT_27465]
2.closely  monitor the subject for AEs/SAEs and laboratory abnormalities
3.obtain a serum sample for pharmacokinetic ( PK) analy sis at the time of the event, 
and three day s after the event (unless otherwise requested by  [CONTACT_22955])
4.document the quantity  of the excess dose as well as the duration of the overdosing 
in the eCRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_227561] e valuation of the subject.
6.9. Treatment after the End of the Study
Subjects will not receive any additional treatment from [COMPANY_004] after completion of the 
study  because the efficacy  of [COMPANY_004]3196165 has not y et been defined. Treatment after the 
end of the stud y will continue as per the standard of care for HOA at the site.
The investigator is responsible for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition, whether or not [COMPANY_004] is providing specific 
post-study  treatmen t.
6.10. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_515262], enzy mes such as C ytochrome P450 (CYP450) can be down-
regulated leading to instances of reduced clearance and increased plasma concentrations 
of administered drugs.  The administration of [COMPANY_004]3196165 can potentially  alter 
circulating cy tokine levels in a patient whose cy tokine levels have been elevated.  This 
may partially  or completely  reverse the impact of cy tokines on CYP450 enzy mes leading 
to changes in the exposure of co -administered drugs whose metabolism is dependent on 
CYP450 enzy mes.  The reports so far suggest the magnitude of drug interaction by  
[CONTACT_515313] (clinically ) is generally  small (less than two -fold) and therefore onl y 
likely  to be clinicall y relevant for CYP450 substrates with a narrow therapeutic index, 
where the dose is individually  adjusted. 
Upon initiation or discontinuation of [COMPANY_004]3196165, therapeutic drug monitoring should 
be performed in subjects being treated with drugs that are CYP450 substrates and hav e a 
narrow therapeutic  index  e.g ., warfarin or theophy lline  2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667761] for several weeks 
after stoppi[INVESTIGATOR_121471] y.
6.10.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_515263] 
(acetaminophen )which may  be taken on an as needed basis up to 4g/day  or to the 
maximum permitted under local label. 
Any use of Paracetamol (a cetaminophen )will be recorded as concomitant medication. 
Subjects will record use of Paracetamol ( acetaminophen )forhand pain on a daily  basis. 
Use of an y other concomitant medications by [CONTACT_515314] y 
visits.
6.10.2. Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_515264]  1 (randomization) until after 
completion of the Week [ADDRESS_667762] also be discontinued for the stated time 
prior to Day  1 (randomization) as follows:
Hydroxy chloroquine must be discontinued at least 3 weeks prior to Day  1.
NSAIDs ( both s ystemic and topi[INVESTIGATOR_2855]) must be discontinued at least 22 day s prior to 
Day 1.
Opi[INVESTIGATOR_515265] -formulated medicines of paracetamol and 
opi[INVESTIGATOR_515266] 22 day s prior to Day  1.
Intra -articular corticosteroids for the targeted joints in hand, hip and knee must be 
discontinued at least 12 weeks prior to Day  1.
Intra -articular injection of hy aluronate for the targeted joints in hand, hip and knee 
must be discontinued at least 26 weeks prior to Day 1.
Any investigational medication must be discontinued at least [ADDRESS_667763], prior to Day  
1 (whichever is longer).
Any physical therap y (including hand splints) must be discontinued at le ast 28 day s 
prior to Day  1
"Nutraceuticals" (e.g. glucosamine and chondroitin) and alternative medicine 
products, unless taken at a stable dose, must be discontinued for a minimum of [ADDRESS_667764] be noted: 
PROs must be administered prior to an y other assessments being performed (at the main 
study  site) to avoid influencing subjects. The appropriate order f or the PROs and 
approximate time required for completion of each, should be:
Borg CR10 Scale (1 question, approx. 1-2 minutes, see SRM for details)
PtGA (1 question, approx. 1 -2 minutes, see Appendix 10)
AUSCAN 3.1 NRS (15 questions, approx. 5 -10 minutes, see SRM for details)
Daily  pain NRS questionnaire (2 questions, approx. 1- 2 minutes, see Appendix 8
and Appendix 9 ) will be completed by [CONTACT_96926], starting on Day 1 of 
screening (although training, including an example pain NRS questionnaire, 
may be given during the Day  1 screening visit at the site). Patients will be 
instructed to complete the pain NRS questionnaire at approximately the same 
time each day  (e.g. between 6pm -10pm).
If assessments are scheduled fo r the same nominal time, THEN the assessments 
should occur in the following order:
1. 12- lead ECG
2.vital signs
3.blood draws.
Note: The timing of the assessments should allow the blood draw to occur at the 
exact nominal time.
The timing and number of planned study  assessments, including safet y, pharmacokinetic, 
pharmacod ynamic/biomarker or others assessments may  be altered during the course of 
the study  based on newly available data (e.g., to obtain data closer to the time of p eak 
plasma concentrations) to ensure appropriate monitoring. 
The change in timing or addition of time points for any  planned stud y 
assessments must be documented in a Note to File which is approved b y the
relevant [COMPANY_004] stud y team member and then archived i n the study  sponsor and 
site study  files, but this will not constitute a protocol amendment. 
The Institutional Review Board (IRB)/Independent Ethics Committee (IEC) will 
be informed of an y safety issues that require alteration of the safet y monitoring 
scheme or amendment of the I nformed Consent Form.  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
46No more than [ADDRESS_667765] Screening
(must be carried out  28 days prior to Day 1)
Screening T&E table notesScreening Day 1 Screening Days 1 -7, at home Screening Day ≥8
 
Informed Consent Daily Pain NRS questionnaire2 Pain NRS eligibility assessment3 1) Where possible, the same individual should 
perform all disease assessments for an 
individual subject (with separate joint assessor).
2) Pain NRS questions should be completed at 
approximately the same time each day 
(recommended between 6pm and 10pm).
3) Eligibility assessment will be based on a 7 
day average of the ‘24h average Pain NRS’ 
question.
4) Subjects must have passed all screening 
assessments, including laboratory tests a nd 7-
day pain NRS assessment, prior to undertaking 
MRI scanning.Inclusion/exclusion criteria MRI4
Demographics
Medical/medication/alcohol history
Con. Med. Review
Vital signs
12-lead ECG
Full Physical Exam
Swollen and tender joints1
Haem/Chem/Urinalysis
HIV, TB, Hepatitis B & Hepatitis C screen
RF, ACPA (anti -CCP)
Pregnancy test (serum)
Urine drug / alcohol screen
Spi[INVESTIGATOR_038] (FEV1, FVC) & D LCO
Pain NRS training
SAE assessment 
 
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
487.1.2. Treatment period Time and Events table
Study events
Screening (≤28 days 
prior to Day 1)Treatment period
Week 20 phone call 
(Day 141  5d)
Follow up (Week 22
(Day 155  7d)Treatment period T&E table notesWeek 0 Wk 1 Wk 2 Wk 3 Wk 4 Wk 6 Wk 8 Wk 10 Wk 12Baseline & Day 
1 treatment visit
Day 3 ( 1d)PK 
biomarker visit
Day 8 ( 1d) 
treatment visit
Day 15 ( 1d) 
treatment visit
Day 22 ( 1d) 
treatment visit
Day 29 ( 1d) 
treatment visit
Day 43 ( 3d) 
treatment visit
Day 57 ( 3d) 
treatment visit
Day 71 ( 3d) 
treatment visit
Day 85 ( 3d) 
treatment visit
Borg CR10 Scale1
See separate T&E table for screening proceduresX X X X X X X X X
Site to contact [CONTACT_515315] 7 days before their Follow-up visit at Week 22
See separate table for follow-up visit procedures1) Perform PROs before any other 
assessments, or procedures, to 
avoid influencing subject.
2) Where possible, the same 
individual should perform all disease 
assessments for an individual 
subject (with separate joint 
assessor).
3) MRI scanning at week [ADDRESS_667766] on a separate day from 
other assessments and may occur 
on Day 85 ( 5d).
4) Before dosing (on dosing days) .
5) Day 1 immunogenicity sample 
includes anti -GM-CSF auto -antibody 
analysis
6) Consenting subjects only. 
7) Pain NRS questions should be 
completed at approximately the 
same time each day (recommended 
between 6pm and 10pm).Patient1and physician global 
assessment2 X X X X X
AUSCAN 3.1 NRS1X X X X X X X X
Brief Physical Exam X X X X X
Vital signs X X X X X
12-lead ECG X4 X
Swollen and tender joints2X X X X X X X X
MRI3X3
Haem/Chem/Urinalysis X X X X X X X X
PK sampling4X X X X X X
Blood Biomarkers4X X X X X X X
Urine drug/alcohol X X
Study treatment dosing X X X X X X X X
Cough, Auscultation, Pulse Oximetry X X X X X X X X X
Spi[INVESTIGATOR_038] (FEV1, FVC) & D LCO X X
Immunogenicity blood sampling X5 X X X
Pharmacogenetics6X
Pregnancy test (urine) X X X X
Post-treatment Interview X
Daily Pain NRS questions7<------------------------------------------- X ------------------------------------- ------ >
SAE/AE assessment <------------------------------------------- X ------------------------------------------- >
Con. medication review <------------------------------------------- X ------------------------------------------- > 
 
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
497.1.3. Follow -up visit and early  withdrawal* procedures list
Subject Follow -up Visit
Task List
Follow -up T&E table notesWeek 22
(Day 155  7d)

Borg CR10 Scale1 1) Perform PROs before any other assessments, or 
procedures, to avoid influencing subject.
2) Assessment will be based on a 7 day average of 
the Pain NRS questions.
3) Where possible, the same individual should 
perform all disease assessments for an individual 
subject (with separate joint assessor).
4) If scheduling MRI on the same day as the follow 
up visit is not possible, the MRI visit may take place 
on a separate day before the Follow -up visit   but it 
must occur within the same Day 155 7day 
window.Patient1and physician global assessment3
Pain NRS assessment2
Vital signs
Full Physical Exam
Swollen and tender joints3
SAE/AE assessment
Con. Med. Review
Pregnancy test (urine)
Haem/Chem/Urinalysis
Immunogenicity
MRI4
PK Sampling
Blood Biomarkers
Cough, Auscultation, Pulse Oximetry
Spi[INVESTIGATOR_038] (FEV1, FVC) & D LCO
*for early  withdrawal, follow Day  85 procedures, then schedule a follow up visit. 
 
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
507.2. Screening and Critical Baseline A ssessments
Cardiovascular medical history /risk factors (as detailed in the eCRF) will be assessed at 
screening.
The following demographic parameters will be captured: y ear of birth, sex, race and 
ethnicity .
Medical/medication/family  history  will be assessed as related to the inclusion/exclusion 
criteria listed in Section 5.  
Starting at Screening Day 1, subjects will complete the daily  pain NRS questionnaire (2 
questions, approx. 1- 2 minutes, see Appendix 8 and Appendix 9 ), for at least [ADDRESS_667767] 
and all subsequent pain NRS questionnaires at home, at approximately  the same time 
each day  (recommended between 6pm- 10pm). Once lab scre ening results are available 
and after completion of at least [ADDRESS_667768]’s eligibility  to continue to participate in screening (and progress to MRI  scan) 
will be determined. 
Eligibility  is based on the ‘24h A verage Pain NRS’ question (see Appendix 8 ), taken over 
7 consecutive day s prior to the assessment. The average of the pain intensity  scores over 
these 7 day s is assessed, and an average of ‘5’ or higher (on the 0 -10 NRS), is required in 
order for the subject to be eligible to continue in screening.
If only  one hand is affected by  [CONTACT_515289], the affected hand 
will be documented at scree ning and used for all assessments. I n cases where both hands 
are affected b y HOA and both meet the inclusion criteria, then the dominant hand will 
be documented at screening and this hand will be used for all MRI assessments 
throughout the stud y.
MRI  of the affected hand will take place onl y if the subject has passed all other screening 
assessments, including all lab assessments and the Pain NRS 7- day assessment. MRI  will 
be the final screening assessment.
All subjects should continue to complete the dail y pain NRS questionnaire until all their 
screening assessments (including MRI) are completed and the final outcome on whether 
they can participate in the study  has been determined. If the subject passes screening and 
is able to participate in the study , they should continue to complete their daily  pain NRS 
questionnaires until the Week [ADDRESS_667769] in the week prior to the follow -up visit at 
Week 22.
7.3. Efficacy
Patient Reporte d Outcomes questionnaires should be completed by  [CONTACT_515316] a clinic visit, in the order specified at the start of Section 7. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
51Efficacy  assessments will be performed at the time points presented in the Time and 
Events Table (Section 7.1).
Efficacy  assessments will include evaluation of hand pain (Pain NRS questionnaire), 
hand function, pain on use and stiffness (AUSCAN 3.1 NRS), disease activity  (patient 
and physician global assessment of disease activity , PtGA/PhGA), and number of tender, 
and swollen joints in their hands. For pain efficacy  assessments the average pain intensity 
over [ADDRESS_667770]’s A ssessment of Hand Pain , Function, Stiffness, and 
Subject’s / Clinician’s A ssessment of Global Disease A ctivity
The patient reported outcome (PRO) questionnaires (Pain NRS, AUSCAN 3.1 NRS, 
Patient Global Assessment of Disease Activity  [PtGA]) will be completed at relevant 
study  visits or at home as described in the Time and Events Table (Section 7.1), and the 
data entered into the eCRF.
Pain intensity  will be assessed by  [CONTACT_1766], at home, using a daily  Pain NRS (0 -10) 
questionnaire. Subjects will record their ‘average hand pain’ and ‘worst hand pain’ 
intensity  over the past 24 hours (see Appendix 8 and Appendix 9 ), they  will also record 
any use of any  rescue paracetamol (acetaminophen) for hand pain over the past [ADDRESS_667771] at approximately  the same time each day  (recommended between 
6pm- 10pm) for the 12 -week treatment period of the study . 
Hand function, pain on use and stiffness will be assessed using the AUSCAN Index.  
Patients will complete the AUSCAN 3.1 NRS at study  visits. 
A global assessment of disease activity  will be completed by  [CONTACT_515317] 
a Patient Global / Phy sician Global Assessment of Disease Activity (PtGA/PhGA) item, 
which asks subjects / clinicians to rate the level of disease activity  today  on an 11 -point 
Numeric Rating Scale (NRS, 0 -10) with anchors ‘Very  well’ and ‘Very  Poor’ for the 
PtGA, and anchors ‘None’ and ‘Extremel y Active’ for the PhGA.
Joint Assessments
To prevent potential biasbecause of observed efficacy  changes, the Joint Assessor must 
not be the treating ph ysician (PI  [INVESTIGATOR_11637] -investigator) or the unblinded drug administrator. 
The Joint Assessor (or designee) should be a rheumatologist or other skilled arthritis 
assessor and will be responsible only  for completing the joint counts.  To ensure 
consistent joint evaluation throughout the trial, individual subjects should preferabl y be 
evaluated b y the same joint assessor for all study visits.
Treating Physician
The Treating Ph ysician (or designee) should be a rheumato logist (or other medically  
qualified phy sician) and will have access to both safet y and efficacy data.  The Treating  2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667772] access to source documents, laboratory  results and eCRFs and will be 
responsible for completing Ph ysician’s Global Asse ssment of Disease Activity , and 
safet y assessments (adverse events, vital signs, concomitant medications, and review of 
laboratory  data).
It is essential that assessments completed by [CONTACT_515318].
7.4. Safet y
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Section 7.1).  Additional time points for saf ety tests such as vital signs, physical exams 
and laboratory  safet y tests may be added during the course of the stud y based on newl y 
available data to ensure appropriate safet y monitoring.
7.4.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitio ns of an AE or SAE can be found in Appendix 4 .
The investigator and their designees are responsible for detecting, documenting and 
reporting events that meet the definition of an AE or SAE. 
[IP_ADDRESS]. Time period and Frequency  for collecting A E and SA E information
Any SAEs assessed as related to study  participation (e.g., protocol- mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be reco rded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact. 
AEs will be collected from the start of Study  Treatment until the follow -up 
contact (see Section [IP_ADDRESS] ), at the time points specified in the Time and Events 
Table (Section 7.1).
Medic al occurrences that begin prior to the start of study  treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the eCRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as in dicated in 
Appendix 4 .
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, if the investigator learns of an y SAE, including a death , at any  
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and asse ssing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
Appendix 4 . 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?”
“Have you had an y (other) medical problems since y our last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit /contact?”
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts.  All SAEs, and non -serious AEs of special interest 
(as defined in Section 7.4.2) will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until the subject is lost to follow -up 
(as defined in Section 5.4). Further information on follow -up procedures is given in 
Appendix 4 .
[IP_ADDRESS]. Cardiovascular and Death Events
For an y cardiovascular events detailed in Section 12.4.3 and all deaths, whether or not 
they are considered SAEs, specific Cardiovascular (CV) and Death sections of the CRF 
will be required to be completed. These sections include questions regardi ng 
cardiovascular (including sudden cardiac death) and non- cardiovascular death. 
The CV CRFs are presented as queries in response to reporting of certain CV Medical 
dictionary  for regulatory  activities (MedDRA) terms. The CV information should be 
recorde d in the specific cardiovascular section of the CRF within one week of receipt of a 
CV Event data query  prompting its completion. 
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_132004] (even 
for non -interventional post -marketing studies ) is essential so that legal obligations and 
ethical responsibilities towards the safet y of subjects and the safety of a product under 
clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
54Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receiv es an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
7.4.2. AEs of Special Interest (A ESIs)
Please see Section 4.7.[ADDRESS_667773] include:
Serious infec tions, including serious respi[INVESTIGATOR_515267].
Opportunistic infections.
Neutropenia
Respi[INVESTIGATOR_515268] (PAP).
oPersistent (for 3 consecutive weeks) reduction in D LCO>15% 
oPersistent (for 3 consecutive weeks) cough and/or dy spnea 
oNon life -threatening pulmonary  changes related to surfactant 
accumulation
Hypersensitivity  reactions including anaph ylaxis.
Injection site reactions
7.4.3. Pregnancy
Details of all pregnancies in female subjects and female partners of male subjects 
will be collected after the start of dosing and until completion of the follow up 
visit at Week 22. 
If a pregnancy  is reported then the investigator should inform [COMPANY_004] withi n 2 
weeks of learning of the pregnancy  and should follow the procedures outlined in 
Appendix 5 .
7.4.4. Physical Exams
A complete ph ysical examination will include, at a minimum, ass essment of the 
Cardiovascular, Respi[INVESTIGATOR_696] , Gastrointestinal and Neurological s ystems. Height 
and weight will also be measured and recorded. 
A brief ph ysical examination will include, at a minimum assessments of the lungs, 
cardiovascular s ystem, and abdom en (liver and spleen).
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
557.4.5. Vital Signs
Vital signs will be measured in semi -supi[INVESTIGATOR_55848] [ADDRESS_667774] olic blood pressure and pulse rate.
Three readings of blood pressure and pulse rate will be taken:
First reading should be rejected
Second and third readings should be recorded in the eCRF.
7.4.6. Electrocardiogram (ECG)
Triplicate 12 -lead ECGs will be obtained a t each time point during the study  using 
an ECG machine that automatically  calculates the heart rate and measures PR, 
QRS, QT, and QTc intervals (based on averaged QTc values of triplicate 
electrocar diograms obtained over a brief, e.g. 5- 10 minute ,recordi ng period). 
Refer to Section 5.4.[ADDRESS_667775] of the safety  monitoring in this study  (refer to 
Section 5.5.1).
The following pulmonary  assessments will be performed at the time points presented in 
the Time and Events Table (Section 7.1)
Cough (See Appendix 7 ).
Borg CR10 Scale (See SRM for details).
Lung auscultation.
Pulse oximetry .
Pulmonary  function tests (PFTs - spi[INVESTIGATOR_038] , gas transfer [D LCO]).
PFTs will be performed by  [CONTACT_447520].  As a general guidance, sites are asked to 
follow the ATS/ERS recommendations for lung function testing [ Miller , 2005a; Miller , 
2005b; Macinty re, 2005].  Spi[INVESTIGATOR_515269] D LCO.  Subjects 
should avoid the following activities prior to undergoing the PFTs:
Smoking within at least 1 hour of testing
Consuming alcohol within 4 hours of testing
Use of bronchodilators within 4 hours of testing
Performing vigorous exercise within 30 minutes of testing
Wearing clothing that substantially  restricts full chest and abdominal expansion
Eating a large meal within 2 hours of testing 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
567.4.8. Immunogenicity
[COMPANY_004]3196165 is a humanized monoclonal antibody that will be delivered by [CONTACT_515319] a soluble target, and for these 
reasons, is considered to be a relatively  low risk of inducing adverse immune responses 
[FDA , 2014].
Serum samples will be collected and tested for presence of antibodies that bind to 
[COMPANY_004]3196165.  Serum samples for testing anti- [COMPANY_004]3196165 antibodies will be collected 
as described in the Time and Events schedule (Section 7.1).  The actual date and time of 
each blood sample collection wil l be recorded.  Details of blood sample collection 
(including volume to be collected), processing, storage and shippi[INVESTIGATOR_515270].
The timing and number of planned immunogenicity  samples may  be altered during the 
course of the stud y, based on newly- available data to ensure appropriate safety  
monitoring.  In the event of a h ypersensitivity  reaction that is either 1) clinically -
significant in the opi[INVESTIGATOR_871], or 2) leads to the subject withdrawing from 
the study , blood samples should be taken from the subject for immunogenicity  testing, at 
the time of the event and again [ADDRESS_667776] dose.
Serum will be tested for the presence of anti- [COMPANY_004]3196165 antibodies using the currently  
approved anal ytical methodology  using a tiered testing schema: screening, confirmation 
and titration steps.  The presence of treatment emergent anti -drug antibodies (ADA) will 
be determined using a [COMPANY_004]3196165 bridging sty le ADA assay  with a bio- analytically  
determined cut point determined during assay  validation.  Samples taken after dosing 
with [COMPANY_004]3196165 that have a value at or above th e cut -point will be considered 
treatment -emergent ADA -positive.  These ADA positive samples will be further 
evaluated in a confirmatory  assay , and confirmed positive samples will be further 
characterized b y assessment of titer.  Results of anti-[COMPANY_004]3196165 antibody testing will 
be reported at the end of the study  and will include incidence and titer.  The presence or 
absence of antibodies to [COMPANY_004]3196165 in dosed subjects will be anal yzed, then 
summarized descriptively and/or graphically  presented.
7.4.9. Clinical Sa fety Laboratory  Assessments
All protocol required laboratory  assessments, as defined in Table 2, must be conducted in 
accordance with the Central Laboratory  Manual, and Protocol Time and Events Schedule 
(Section 7.1). Laboratory requisition forms must be completed and samples must be 
clearl y labelled with the subject number, protocol number, site/centre number, and visit 
date. Details for the preparation and shipment of samples will be provided by [CONTACT_515320]. Reference ranges for all 
safet y parameters will be provided to the site by [CONTACT_159873].
All study -required laboratory  assessments will be performed b y acentral laboratory . 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
57If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorded in the eCRF.
Refer to the Central Laboratory  Manual for appropriate processing and handling of 
samples to avoid duplicate and/or additional blood draws.
Haematology , clinical chemistry , urinal ysis and additional parameters to be tested are 
listed in Table 2. 
Table 2 Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Haematology Platelet Count RBC Indices :WBC count with Differential :
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry  1BUN Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Calcium Alkaline phosphatise Albumin
Routine 
Urinaly sisSpecific gravit y
pH, glucose, protein, blood and ketones b y dipstick
Microscopic examination (if blood or protein is abnormal)
Urine pregnancy
Other 
Screening 
TestsHIV
Hepatitis B surface antigen (HBsAg)
Hepatitis B core antibody  (HBcAb)
Hepatitis C (Hep C antibody )
Diagnostic TB test: either QuantiFERON Gold test or T -spot test
FSH and estradiol (as needed in women of non-child bearing 
potential only )
Alcohol and drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651])
Serum hCG Pregnancy  test (as needed for women of child bearing 
potential) 2
NOTES :
1.Details of L iver Chemistry  Stoppi[INVESTIGATOR_131963] -
Up Assessments after liver stoppi[INVESTIGATOR_31777] 
5.4.[ADDRESS_667777] dose of study treatment 
should be repeated until the values return to normal or baseline.  If such values do not 
return to normal within a period judged reasonable by  [CONTACT_093], the etiology  
should be identified and the sponsor notified.
7.5. Pharmacokinetics
7.5.1. Blood Sample Collection
Blood samples for pharmacokinetic (P K) anal ysis of [COMPANY_004]3196165 will be collected at 
the time points indicated in Section 7.1, Time and Events Table.  The actual date and 
time of each blood sample coll ection will be recorded.  The timing of PK samples may  be 
altered and/or PK samples may  be obtained at additional time points to ensure thorough 
PK monitoring.  
Collection, processing, storage and shippi[INVESTIGATOR_515271]. 
7.5.2. Sample A nalysis
Serum anal ysis will be performed under the control of PTS -DMPK/Scinovo, 
GlaxoSmithKline, the details of which will be included in the Central Laboratory  
Manual. Concentrations of [COMPANY_004]3196165 will be determined in serum samples usi ng the 
currentl y approved bioanalytical methodology. Raw data will be archived at the 
bioanaly tical site (detailed in the Central Laboratory  Manual).
7.6. Biomarkers and Imaging
7.6.1. Magnetic Resonance Imaging
Each subject’s affected hand (corresponding to the affe cted hand which is determined and 
documented at screening) will be imaged b y MRI at screening, week 12 and week 22 (see 
Section 7.1). If a scanning failure occurs at any  visit, if feasible a rescan is allowed within 
10days of the failed scan after consultation and agreement with the [COMPANY_004] medical 
monitor. There will be a minimum of [ADDRESS_667778] (non- anon ymised) for clinical 
abnormalities.
7.6.2. Novel Biomarkers
With the subject’s consent, blood samples will be collected during this study  and may  be 
used for the purposes of measuring novel biomarkers to identify  factors that may  
influence osteoarthritis disease severit y and progression, and/or medically related 
conditions, as well as the biological and clinical responses to [COMPANY_004]3196165. If relevant, 
this approach will be extended to include the identification of biomarkers associated with 
adverse events. 
Blood samples for novel biomarkers will be collected at the time points indicated in 
Section 7.1 and processed to plasma (as summarised below).  The timing of the 
collections may  be adjusted on the basis of emerging pharmacokinetic or 
pharmacod ynamic (PD) data from this study  or other new information in order to ensure 
optim al evaluation of the PD endpoints.  
Collection, processing, storage and shippi[INVESTIGATOR_515272]. 
Novel candidate biomarkers and subsequently  discovered biomarkers of the biological 
response associated with osteoarthritis or medically  related conditions and/or the action 
of [COMPANY_004]3196165 may  be identified by  [CONTACT_515321], but not limited 
to: 
Biochemical anal ysis.
Proteome anal ysis.
Metabolomic anal ysis.
All samples will be retained for a maximum of [ADDRESS_667779] completes 
the trial. 
The results of these biomarker investigations and other exploratory  endpoints, may be 
reported separatel y from the main study report. This will detailed in the reporting and 
analysis plan (RAP).
7.7. Genetics
Information regarding genetic research is included in Appendix [ADDRESS_667780]-treatment interviews will be conducted as shown in the Time and Events Table 
(Section 7.1) to explore subjects’ experience with study  treatment. Post -treatment 
interviews are qualitative interviews conducted with study  subjects to capture subject 
experiences in drug development on completion of participation in a clinical study . 
Interview ques tions designed to fully assess a subject’s experience with a study  
medication are administered in a semi -structured format by  a trained interviewer. Subject 
feedback will be captured in a data collection sheet as well as being audio -taped for 
subsequent tr anscription and qualitative anal ysis. The interview technique and questions 
are described in Appendix 12 and training as well as training material references will be 
provide d to site personnel who will administer the interviews.
8. DATA MANAG EMENT
For this study  subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other 
sources in a validated data system. 
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medic ations terms will be coded using MedDRA 
(Medical Dictionary for Regulatory  Activities) and an internal validated 
medication dictionary , [COMPANY_004]Drug.  
eCRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_515273] .  Subject 
initials will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy.
For this study  subject data will be collected in electronic [COMPANY_004] defined case report 
forms (eCRF). For the PRO component, the data will be collected and managed 
on the modality  as determined prior to the start of the study .
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The primary  endpoint of the study  is to evaluate the change from baseline in 24h average 
hand pain intensity  at Week 6, as measured by  [CONTACT_515291] (NRS) 
(see Appendix 8 ) averaged over the [ADDRESS_667781] a minimal significant 
difference over placebo of approximately  2 points in the change from baseline in the 24h 
average Pain NRS at Week 6 of the 12 week treatment period and has approximately  
80% power to detect a difference of 2.7 points assuming an SD = 3 and a 5% significanc e 
level.  The estimate of variability  is based on sample size assumptions from a literature 
review of two studies in knee OA using a pain NRS [ Steigerwald ; 2012, Afilalo; 2010].
9.2.2. Sample Size Sensitivity
The power of the stud y will be affected b y changes from the assumed estimate of the SD 
and Table [ADDRESS_667782] on power and the minimally  significant difference under 
varying estimates of the SD, and the number of subjects needed for 80% power.
Table [ADDRESS_667783] a Difference -2.7 points for Change from baseline in 
24h average Pain NRS at 6 Weeks under Vary ing Estimates of the SD
SD Estimate Power with 20 
Subjects / armMinimal Significant Difference 
with 20 subjects / armN / arm for 80% power
2.5 91% -1.6 15
3 80% -2 20
3.5 66% -2.2 28
9.2.3. Sample Size Re -estimation or A djustment
No Sample size re-estimation is planned.
9.3. Data Analysis Considerations
9.3.1. Analysis Populations
Intent to Treat (ITT) population: The I TT population is defined as all subjects who 
were randomised to treatment and who received at least one dose of stud y treatment. This 
population will be based on the randomised treatment group.
Safety population: The safet y population is defined as all subjects who receive at least 
one dose of stud y treat ment. This population will be based on the actual treatment 
received.
Pharmacokinetic (PK) population: The PK population is defined as all subjects who 
are in the ‘Safet y’ population and who have at least one valid PK assessment.
9.3.2. Interim A nalysis
An interi m anal ysis will be performed during the study  to review the available PK data 
and target engagement biomarkers. The timing of this analy sis will coincide with other  2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667784]. Unblinded data will be shared 
with members of Clinical Pharmacology  Modelling and Simulation (CPMS), Clinical 
Statistics and [COMPANY_004] study  team members who have no involvement in the acquisition of 
the data or direct contact [CONTACT_190063]. No other members of the [COMPANY_004] stud y team will be 
unblinde d to this data. 
Another formal interim analy sis may  be conducted on the key  safety , primary  efficacy  
and key  secondary  endpoints in this study . The purpose of this interim will be to help 
with decision- making regarding the subsequent clinical development of [COMPANY_004]3196165 for 
OA. The timing of this analy sis will be once a minimum of [ADDRESS_667785] completed 
day 43 (Week 6) .Full details will be provided in the RAP which will be available prior 
to the data being unblinded. Unblinded data will only be shar ed with selected members 
of the [COMPANY_004] study  team. No members of the [COMPANY_004] study  team who have involvement in 
the acquisition of the data or who have direct contact [CONTACT_515322].
Recruitment will continue while the interim anal yses are being conducted.
For both interim anal yses,unblinded summary  level data will be available and if required 
anony mised individual data will be available on request. Only the study  
pharmacokineticist or study statistician generating the interim analysis results will be 
unblinded to individual subject treatment allocations.
9.4. Key Elements of A nalysis Plan
Full details of all anal yses will be provided in the RAP.
9.4.1. Primary  Analyses
The primary  endpoint will be anal ysed using a repeated measures model ( MMRM) 
adjusted for baseline pain score, treatment group, visit and the visit by  [CONTACT_515323], patient as a random effect and day  within patient as a repeated 
effect, using an unstructured covariance matrix.  The point estima tes and corresponding 
95% confidence intervals for the treatment differences will be constructed, using the 
residual error from the repeated measures model.  Least squares means and 95% 
confidence intervals over time for each treatment group will be plotte d.  Further 
sensitivity  anal yses will be conducted to assess the impact of missing data and non -
parametric anal yses may  be conducted if the normality  assumption does not hold.
9.4.2. Secondary  Analyses
Continuous endpoints will be anal ysed using the same methods as the primary  endpoint.
Binary  endpoints, e.g. the proportion of subjects that achieve a 30% reduction in the Pain 
NRS score from baseline, will be summarised using counts and proportions in remission 
and anal ysed using a Generalised Estimating Equation ( GEE) model comparing 
[COMPANY_004]3196165 with placebo at each time point.  Subjects with missing Pain NRS scores 
will be considered as non -responders. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
639.4.3. Other A nalyses
All safet y evaluations will be based on the Safety population.  Clinical interpretation will 
be bas ed upon review and display s of each safet y parameter, including adverse events 
(AE), serious adverse events (SAE) and AEs of special interest.  Anal yses of AEs by  [CONTACT_515324].
Full details of all summaries and analy ses will be included in the RAP.
10. STUDY GOVERNANCE CON SIDERATIONS
10.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical tr ial 
registers before enrolment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conduc ted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed consent
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above proc edures, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subject prior to participation 
in the study  (and prior to any  wash out time needed to discontinue prohibited 
medication).
The IEC/I RB, and where applicable the regulatory authority , approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurr ently submitted for 
approval unless regulation requires separate submission.   2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
64Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol where required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
10.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] (or designee) monitors will contact [CONTACT_515325], study  requirements, and their 
responsibilities to satisfy  regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the CRF will 
serve as the source document.
[COMPANY_004] (or designee) will monitor the study  and site activity  to ver ify that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requiremen ts.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after completion of the study . 
In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any findings/relevant issues and to implement any 
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] (or 
designee) monitor will conduct site closure activities with the investigator or site 
staff, as appropriate, in accordance with applicable regulations including GCP, 
and [COMPANY_004] Standard Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or prematurel y discontinue this 
study  at an y time for reasons including, but not l imited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more 
or at all sites.   2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
65If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with the investigator or th e head of the medical institution (where 
applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the study is suspended or prematurely discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study . [COMPANY_004] will also promptly  
inform the relevan t regulatory  authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution (where applicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain all site study  records (except for 
those required b y local regulations to be maintained elsewhere), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory  inspection) and must be available for re view 
in conjunction with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and retrieval stan dards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by 
[CONTACT_515326], [COMPANY_004] 
standards/procedures, and/or institutional requirements.  
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off- site facility  or transfer of 
ownership of the records in the event the investigator is no longer associated with 
the site. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10700].7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applica ble regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subject s, as 
appropriate.
[COMPANY_004] will provide the investigator with the randomization codes for their site only  after 
completion of the full statistical analy sis.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscr ipt for publication will be in accordance with [COMPANY_004] Policy . 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10701]. REFERENCES
Afilalo M, Etropolski M, Kuperwasswe B, et al.  Efficacy  and Safet y of Tapentadol 
Extended Release Compared with Ox ycodone Controlled Release for the Management of 
Moderate to Severe Ch ronic Pain related to Osteoarthritis of the Knee. Clin .Drug .
Investig .2010; 30 (8): 489-505.
Altman RD. Pharmacological therapi[INVESTIGATOR_515274]. Drug Aging 2010 ;
27:[ADDRESS_667786] M, et al. MOR103, a human monoclonal antibody  to 
granulocy te-macrophage colony -stimulating factor, in the treatment of patients with 
moderate rheumatoid arthritis: results of a Phase Ib/IIa randomised, double -blind, 
placebo- controlled, dose -escalation trial. Ann .Rheum. Dis. 2015 Jun; 74(6):1058-64.
Bell AL, Magill MK, McKane WR. Measurement of colony- stimulating factors in 
synovial fluid: potential clinical value. Rheumatol. Int. 1995; 14:177 -82.
Bellam y N, Campell J, Haraoui B et al. Clinimetric properties of the AUSCAN 
Osteoarthritis Ha nd Index: an evaluation of reliability , validity  and responsiveness. 
Osteoarthritis and Cartilage 2002; 10:863 -869.
Berenbaum F, Rajzbaum G, Amor B et al. Evidence for GM -CSF receptor expression in 
synovial tissue. An analysis by  [CONTACT_31576] -quantitative poly merase chain reaction on 
rheumatoid arthritis and osteoarthritis sy novial biopsies. European C ytokine Network 
1994; 5(1):43 -46.
Bijlsma JWJ, Berenbaum F, Lafeb er FPJG. Osteoarthritis: an update with relevance of 
clinical practice. The Lancet 2011; 377:2115-2125.
Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB. 
Arthritis Rheum. 2010; 62:647 –657.
Bowes MA, Guillard G, Gill E, et al.   Novel quantification of MRI  provides a more 
sensitive outcome measure than RAMRI S. [abstract]. Arthritis Rheum .2014; 66 I ssue 
S10 :pages S1 -S1402 .
Cao Y. Second generation minimal phy siologically -based pharmacokinetic model for 
monoclonal antibodies. Journal o f Pharmacokinetics & Pharmacod ynamics 2013; 40:597 -
607.
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age- Related Macular 
Degeneration (AMD) Susceptibility  Gene CFH and Treatment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464 .
Chevalier X, Ravaud P, Matheu E, et al. Adalimumab in patients with hand osteoarthritis 
refractory  to analgesics and NSAIDs: a randomised, multicentre, double-bl ind, placebo -
controlled trial. Annals of Rheumatic Disease 2014; 0:1–9. doi:10.1136/annrheumdis -
2014-205348. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
68Choy  EH, Connolly  DJ, Rapson N, et al. Pharmacokinetic, pharmacod ynamic and 
clinical effects of a humanized IgG1 anti -CD4 monoclonal antibody  in the peripheral 
blood and sy novial fluid of rheumatoid arthritis patients. Rheumatology  (Oxford) 2000;
39:1139-46.
Common Terminology  Criteria for Adverse Events (CTCAE), v 4.0, Published: May  28, 
2009.  (v4.03: June 14, 2010) http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-
14_QuickReference_8.5x11.pdf.
Cook AD, Pobjoy  J, Sarros S, et al. Granulocy te-macrophage colon y-stimulating factor is 
a key  mediator in inflammatory  and arthritic pain. Ann. Rheum .Dis. 2013 Feb;
72(2):265-70. 
Cook AD, Pobjoy  J, Steidl S, et al. Granulocyte -macrophage colon y-stimulating factor is 
a key  mediator in experimental ost eoarthritis pain and disease development. Arthritis 
Res. &Ther .2012; 14, R199 
Dang PM, Dewas C, Gaudry  M, et al. Priming of human neutrophil respi[INVESTIGATOR_515275]/macrophage colony -stimulating factor (GM- CSF) involves partial 
phosphory lation of p47(phox). J .Biol.Chem .1999; 274:[ZIP_CODE]-8.
Farahat MN, Yanni G, Poston R, Panay i GS. Ann .Rheum .Dis. 1993; 52:870 –875.
Farrar JT, Troxel AB, Stott C, et al . Validity , reliability , and clinical importance of 
change in a 0 -10 numeric rating scale measure of spasticity : A post hoc analy sis of a 
randomoized, double -blind placebo -controlled trial. Clinical Therapeutics 2008; 30:974 -
985.
Farrar JT, Young JP, Moreaux L , et al. Clinical importance of changes in chronic pain 
intensity  measured on an 11 -point numerical pain rating scale. Pain 2001; 94:149-158
Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD. Granulocy te-macrophage colony -
stimulating factor (CSF) and macrophage CSF- dependent macrophage phenoty pes 
display  differences in cy tokine profiles and tr anscription factor activities: implications for 
CSF blockade in inflammation. J .Immunol . 2007; 178,5245-52.
Food and Drug Administration (FDA), Center for Drug Evaluation and Research 
(CDER), Center for Biologics Evaluation and Research (CBER) (2014). Gui dance for 
industry : Immunogenicity Assessment for Therapeutic Protein Products. (FDA 
Mary land).
Gasson JC. Molecular physiology  of granulocy te-macrophage colon y-stimulating factor. 
Blood 1991; 77:1131-45.
Gelber AC. Conventional medical therap y for osteoar thritis: current state of the evidence. 
Curren t Opi[INVESTIGATOR_166036] R heumatology , 2015; 27:313 -317.
Gomez -Cambronero J, Horn J, Paul CC, Baumann MA. Granulocy te-macrophage 
colony -stimulating factor is a chemoattractant cy tokine for human neutrophils:  2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667787]. J. Immunol . 2003;
171:6846-55.
Gorin MB. Genetic insights into age -related macular degeneration: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467 -486.
[COMPANY_004] Document Number 2014N190256_00, “[COMPANY_004]3196165 I nvestigator's Brochure.” 
Investigator's Brochure version 7, 24thNovember 2014.
[COMPANY_004] Document Number 2014N210890_04, “ A Phase IIb, Double -Blind, Placebo -
Controlled, Dose- Adaptive, Study  of the Efficacy  and Safet y of [COMPANY_004]319616 5 in 
Combination with Methotrexate Therap y, in Subjects with Active Moderate -Severe 
Rheumatoid Arthritis Despi[INVESTIGATOR_515276].” Protocol 201755 
amendment 04, 1stMay 2015.
[COMPANY_004] Document Number 2015N226819_00,“Supplement to [COMPANY_004]3196165 Investig ator's 
Brochure.” Investigator's Brochure version 7, Supplement no. 1, 21stJanuary 2015.
Hamilton JA, Achuthan A. Colony  stimulating factors and m yeloid cell biology  in health 
and disease. Trends Immunol . 2013; 34:81 -9.
Hamilton JA, Anderson GP. GM -CSF bi ology . Growth Factors 2004; 22:225 -31.
Haraoui B, Pelletier JP, Cloutier JM, Faure MP, Martel- Pelletier J. Arthritis Rheum. 
1991; 34:153 –163.
Hart PH, Vitti GF, Burgess DR, et al. Activation of human monocy tes by  [CONTACT_515327]-
macrophage colon y-stimulating factor: increased urokinase- type plasminogen activator 
activity . Blood 1991; 77:841 -8.
Hatcher RA, Trussell J, Nelson AL, et al, editors. Contraceptive Technology . 20thedition. 
Atlanta, Georgia: Ardent Media, Inc., 2011: 50. Table 3-2.
Haugen, I. K., Østergaard, M., Eshed, I., et al. Iterative development and reliability  of the 
OMERACT Hand Osteoarthritis MRI  Scoring S ystem. Journal of Rheumatology  2014;
41(2), 386 –391.
Haworth C, Brennan FM, Chantry  D et al. Expression of granulocy te-macrophage 
colony -stimulating factor in rheumatoid arthritis: regulation by  [CONTACT_98416] -
alpha. Eur . J.Immunol .1991 ;21(10):2575-9.
Haywood L, McWilliams DF, Pearson CI, et al. Inflammation and angiogenesis in 
osteoarthritis. Arthritis Rheum. 2003; 48:2173–2177.
Iannone F, Lapadula G. The pathoph ysiology  of osteoarthritis. Aging Clin .Exp. Res. 
2003; 15:364 –372.
Kloppenburg M, Maheu E, Kraus VB, et al . OARSI  clinical trial recommendations: 
design and conduct of clinical trials for hand osteoarthritis. Osteoarthritis and Cartilage 
2015; 23:772-786. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
70Kortekaas MC, Kwok WY, Reijnierse M, et al. Magnetic Resonance Imaging in Hand 
Osteoarthritis: I ntraobserver Reliability  and Criterion Validity  for Clinical and Structural 
Characteristics. Journal of Rheumatology  2015; 42; 1224 -1230.
Kwok WY, Kloppenburg M, Rosendaal FR, et al. Erosive hand osteoarthritis: its 
prevalence and clinical impact in the general population and sy mptomatic hand 
osteoarthritis. Annals of Rheumatic Disease 2011; 70: [ADDRESS_667788]. 1999; 103:563 -9.
Macinty re N, Crapo RO, Viegi G, et al. Standardisation of the single- breath 
determination of carbon monoxide uptake in the lung. Eur .Respir . J. 2005; 26:720 -35.
Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and 
activation. Eur . J.Immunol . 2007; 37:14 -6.
Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. 
Eur.Respir . J.2005a; 26:153 -61.
Miller MR, Hankinson J, Brusasco V, et al . Standardisation of spi[INVESTIGATOR_038] . Eur .Respir . J.
2005b; 26:319 -38.
Pejovic, M. Determination of the ap parent s ynovial permeability in the knee joint of 
patients suffering from osteoarthritis and rheumatoid arthritis. British Journal of 
Rheumatology 1995; 34:520 -524.
Poole JL . Measurement of hand function. Arthritis Care & Research 2011; 63:S189-
S199.
Salaf fi F, Stancati A, Silvestri CA, et al. Minimal clinical important changes in chronic 
musculoskeletal pain intensity  measured on a numerical rating scale. European Journal of 
Pain 2004; 8:283 -291.
Sowers M, Jannausch M, Stein E, Jamadar D, Hochberg M, Lacha nce L. Osteoarthritis 
Cartilage 2002; 10:595 –601.
Spector TD, Hart DJ, Nandra D, Do yle DV, Mackillop N, Gallimore JR, Pepy s MB. 
Arthritis Rheum. 1997; 40:723 –727.
Stanley  E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony -stimulating 
factor -deficient mice show no major perturbation of hematopoiesis but develop a 
characteristic pulmonary  pathology . Proc .Natl. Acad. Sci. [LOCATION_003] 1994; 91:5592-6.
Steidl S, Ratsch O, Brocks B, Durr M, Thomassen- Wolf E.  I n vitro affinity  maturation of 
human GM -CSF antibodies by  [CONTACT_515328]- diversification. Molecular Immunology  
2008; 46(1):135 -144.   
Steigerwald I, Müller M, Kujawa J, Balblanc J, Calvo- Alén J. Effectiveness and safet y of 
tapentadol prolonged release with tapentadol immediate release on -demand for the  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
71management of severe, chronic osteoarthritis -related knee pain: results of an open label, 
phase 3b study .  Journal of Pain R esearch 2012; 5:121-138.
Stone AV, Vanderman KS, Willey  JS, et al. Osteoarthritis Cartilage 2015; 23(10):1780 -9.
Towheed TE. S ystemati ce review of therapi[INVESTIGATOR_515277] d. 
Osteoarthritis and Cartilage 2005; 13:455 -462. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10702]. APPENDICES
12.1. Appendix 1 –Abbreviations and Trademarks
Abbrev iations
ACPA Anti- cyclic citrullinated protein antibody
ACR American College of Rheumatology
ADA Anti- drug antibody
AE Adverse event
AESI Adverse events of special interest
ALT Alanine transaminase
AMD Age-related macular degeneration
AST Aspartate transaminase
ATS American Thoracic Society
AUC Area under the curve
AUSCAN Australian Canadian Hand Osteoarthritis Index
BAL Bronchoalveolar lavage
βhCG Beta-subunit human chorionic gonadotropin
BCG Bacillus Calmette -Guérin
CCP Cyclic citrullinated peptide
CD4 Cluster of differentiation antigen 4
Cl Clearance
CL/F total body  clearance from plasma after SC administration
COPD Chronic obstructive pulmonary  disease
CONSORT Consolidated Standards of Reporting Trials
CPK Creatine phosphokinase
CPMS Clinical Pharmacology , Modelling and Simulation
C[COMPANY_003] Calcium py rophosphate deposition disease
CRF Case Report Form
CRP C-reactive protein
CTC Common terminology  criteria
CV Cardiovascular
CYP450 Cytochrome P450
DAS28 Disease activity  score for [ADDRESS_667789] High -resolution computed tomograph y
HRT Hormone replacement therap y
HV Health y volunteer
IB Investigator’s brochure
IC50 The half maximal inhibitory  concentration
ICH International Conference on Harmonization
IEC Independent Ethics Committee
Ig Immunoglobulin
IL-[ADDRESS_667790]
PIP Proximal interphalangeal
PtGA Patient’s Global Assessment
PhGA Physician’s Global Assessment
PK Pharmacokinetics
PRO Patient Reported Outcome
PTS-DMPK Platform Technologies and Science -Drug Metabolism and 
Pharmacokinetics
QTc corrected QT interval
QTcB QT duration corrected for heart rate b y Bazett’s formula
QTcF QT duration corrected for heart rate b y Fridericia’s formula
RA Rheumatoid arthritis
RAMRI Q Rheumatoid Arthritis Magnetic Resonance Imaging 
Quantitative Score
RAP Reporting and anal ysis plan
RANKL Receptor Activator of Nuclear factor -κB ligand
RF Rheumatoid factor
RNA Ribonucleic acid
SC Subcutaneous
SAE Serious adverse event
SRM Study  Reference Manual
t½ Elimination half -life
TB Mycobacterium tuberculosis
TNF Tumor necrosis factor
TNFα Tumor necrosis factor alpha
ULN Upper limit of normal
ve interstitial volume
vp plasma volume
Vss/F total volume of distribution after SC administration 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
75Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_515329] 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10703].2. Appendix 2 –Liver Safety  Required A ctions and Follow up 
Assessments
Phase II liver chemistry stoppi[INVESTIGATOR_301131] y and evaluate liver event etiology (in alignment with the 
FDA premarketing c linical liver safet y guidance).  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Phase II liver chemistry stoppi[INVESTIGATOR_420682] –Liver St oppi[INVESTIGATOR_53053]- absolute ALT  5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete an 
SAE data collection tool if the event also meets 
the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge subject with study 
treatment unless allowed per protocol and [COMPANY_004] 
Medi cal Governance approval is granted (refer 
to Section [IP_ADDRESS] .)
If restart/rechallenge not allowed per protocol 
or not granted, permanently discontinue study Viral hepatitis serology4
Blood sample for pharmacokinetic (PK) 
analysis, obtained within a week after 
last dose5
Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications 
on the concomitant medications report  2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667791] in the study 
for any protocol specified follow up assessments
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin ) and perform 
liver event follow up assessments within  24 hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline 
A specialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-72 
hrs 
Monitor subjects weekly until liver chemistries 
resolve, stabilize or return to within baselineform including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti- liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential 
acetaminophen contribution to liver 
injury in subjects with definite or likely 
acetaminophen use in the preceding 
week [ James , 2009]). NOTE: not 
required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver 
Imaging and/or Live r Biopsy CRF 
forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be rela ted to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibod y (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.)  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971]. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
78Phase II liver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monit oring Criteria –Liver Monitoring Event
Criteria Actions
ALT  3xULN and <5xULN andbilirubin 
<2xULN , without symptoms believed to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeksNotify the [COMPANY_004] medical monitor within [ADDRESS_667792] safety. 
Subject can continue study treatment 
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779 -1784. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10704].3. Appendix 3 –Genetic Research
Genetics –Background
Naturall y occurring genetic variation may  contribute to inter -individual variability in 
response to medicines, as well as an individual's risk of developi[INVESTIGATOR_42259]. 
Genetic factors associated with disease characteristics may  also be associated with 
response to therap y, and could help to explain some clinical study outcomes. For 
example, genetic variants associated with age- related macular degeneration (AMD) are 
reported to account fo r much of the risk for the condition [ Gorin , 2012] with certain 
variants reported to influence treatment response [ Chen, 2012]. Thus, knowledge of the 
genetic etiology  of disease may  better inform understanding of disease and the 
development of medicines. Additionally , genetic variability  may  impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacod ynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficacy  and/or s afety) observed in a clinical study.
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including an y treatment regimens under investigati on in 
this study  or any  concomitant medicines;
HOA susceptibility , severity , and progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused ca ndidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.   Analy ses may  be performed using data 
from multiple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting and Analysis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
80Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.  
A 6 ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. 
A blood sample is collected at the baseline visit, after the subject has been 
randomized and provided informed consent for genetic research. Instructions for 
collection and shippi[INVESTIGATOR_131977]. The DNA from the blood sample may  undergo quality  control analy ses to 
confirm the integrit y of the sample. If there are concerns regarding the quality  of 
the sample, th en the sample may  be destroy ed. The blood sample is taken on a 
single occasion unless a duplicate sample is required due to an inabilit y to utilize 
the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study.   This number can be traced or linked back to 
the subject by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored sec urely and may be kept for up to [ADDRESS_667793] 
completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only use samples collected from the study  
for the purpose state d in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not wish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdraws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample  2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667794] sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of withdrawn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then the investigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
reconciliation process.  In this instance a sample destruction form will not be available to 
include in the site files.
Provision of Study Results and Confidentiality  of Subject’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the r esults in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employers of individual genoty pi[INVESTIGATOR_131978]’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generally preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10705].4. Appendix 4 –Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
12.4.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporally associated with the use of a medicinal product, wheth er or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal p roduct.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New c onditions detected or diagnosed after study  treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequ elae).
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will be reported if they  fulfil the definition 
of an AE or SAE.
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_99479]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
83condition.
Medical or surgical proced ure (e.g., endoscopy , appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.4.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_446388]/sy mptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
a.Results in death
b.Is life -threatening
NOTE:
The term 'life-threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_515278]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_42979], 
the event is serious.  When in doubt a s to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability/incapacity
NOTE:
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
84and accidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23951].  These should als o be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
g. Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
12.4.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebro vascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10706].4.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the inve stigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004], AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subject identifiers , with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_131976].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
Subject -completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the study .
Responses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accordance with standard scoring and statistical procedures detailed b y 
the scale’s developer.
The use of a single question from a multidimensional health survey  to designate a 
cause -effect relationship to an AE is inappropriate.
12.4.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the definition of an SAE. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
86Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB ) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial tr ansmission of the SAE data to [COMPANY_004].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determining regulato ry 
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.
If a subject dies durin g participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopathology .
 New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10707].4.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the [COMPANY_004] Medical Monitor.
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the elec tronic data collection tool (e.g., 
InForm s ystem) will be taken off- line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the [COMPANY_004] 
Medical Monitor by  [CONTACT_756].
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10708].5. Appendix 5 –Contraception eligibility  criteria for female and 
male subjects
12.5.1. Males:
Male subjects with female partners of child bearing potential must comply  with the 
following contraception requirements from the time of first dose of stud y medication 
until [ADDRESS_667795] dose of study  medication.
a.Vasectom y with documentation of azoospermia. The documentation on male 
sterility  can come from the site personnel’s: review of subject’s medical records, 
medical examin ation and/or semen anal ysis, or medical history  interview. 
b. Male condom plus partner use of one of the contraceptive options below that 
meets the SOP effectiveness criteria including a <1% rate of failure per year, as 
stated in the product label:
Contracep tive subdermal implant
Intrauterine device or intrauterine s ystem
Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011] 
Injectable progesto gen [ Hatcher , 2011]
Contraceptive vaginal ring [ Hatcher , 2011]
Percutaneous contraceptive patches [ Hatcher , 2011]
These allowed methods of contracep tion are only  effective when used consistently , 
correctly  and in accordance with the product label.  The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
Male subjects should not donate s perm during the course of the stud y and should follow 
local guidelines thereafter.
12.5.2. Females: 
A female subject is eligible to participate if she is not pregnant (as confirmed by  a 
negative serum human chorionic gonadotrophin [βhCG] test), not lactating and at least 
one of the following conditions applies:
a.Non-reproductive potential defined as:
Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
89Hysterectomy
Documented Bilateral Oophorectom y
Postmenopausal defined as 12 months of spontaneous amenorrhea in 
questionable cases a blood sample with simultaneous follicle stimulating 
hormone (FSH) and estradiol levels consistent with menopause (refer to 
laboratory  reference ranges for confirmatory  levels).  Females on hormone 
replacement therap y (HRT) and whose menopausal status is in doubt will be 
required to use one of the highl y effective contraception methods if they wish to 
contin ue their HRT during the stud y.  Otherwise, they must discontinue HRT to 
allow confirmation of post- menopausal status prior to study enrolment.
b.Reproductive potential and agrees to follow one of the options listed in the 
Modified L ist of Highl y Effective Me thods for Avoiding Pregnancy  in Females of 
Reproductive Potential (FRP) (see Section 12.5.3) from [ADDRESS_667796] of Highly Effective Methods for Avo iding Pregnancy  
in Females of Reproductive Potential (FRP)
The list does not apply  to FRP with same sex partners or for subjects who are and will 
continue to be abstinent from penile-vaginal intercourse on a long term and persistent 
basis, when this is the ir preferred and usual lifest yle. Periodic abstinence (e.g. calendar, 
ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not acceptable 
methods of contraception.
Contraceptive subdermal implant
Intrauterine device or intrauterine s ystem
Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011])
Injectable progestogen [ Hatcher , 2011]
Contraceptive vaginal ring [ Hatcher , 2011]
Percutaneous contraceptive patches [ Hatcher , 2011]
Male partner sterilization with documentation of azoospermia prior to the 
female subject's entry  into the study , and this male is the sole partner for 
that subject [ Hatcher , 2011].  The documentation on male sterility  can 
come from the site personnel’s: review of subject’s medical records, 
medical e xamination and/or semen anal ysis, or medical history  interview 
provided b y her or her partner.
If using hormonal contraceptives, including oral, injections, implants, and patches, a 
secondary  method of contraception must be used. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667797] label.  The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
12.5.4. Collection of Pregnancy  Information (female subjects)
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within [ADDRESS_667798]'s pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow-up will not be required for longer th an 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is consid ered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as described in Appendix [ADDRESS_667799] who becomes pregnant while participating will discontinue 
study medication and be withdrawn from the study.
12.5.5. Collection of Preg nancy  Information (female partners of male 
subjects)
Investigator will attempt to collect pregnancy  information on any  female partner of a 
male study  subject who becomes pregnant while participating in this study .
After obtaining the necessary  signed infor med consent from the female partner 
directly , the investigator will record pregnancy  information on the appropriate form 
and submit it to [COMPANY_004] within 2 weeks of learning of the partner’s pregnancy
Partner will also be followed to determine the outcome of th e pregnancy .  
Information on the status of the mother and child will be forwarded to [COMPANY_004]. 
Generally , follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery  date.  An y termination of the pregnancy  will be reported regardless of feta l 
status (presence or absence of anomalies) or indication for procedure. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10709].6. Appendix 6 –Recommended Pulmonary  Assessment 
Algorithms
12.6.1. Follow -up A lgorithms
The following assessment algorithms are recommendations for follow -up  triggered by  
[CONTACT_515330], spi[INVESTIGATOR_038] /DLCO, compared with baseline (as detailed in 
Section 5.5.1).  Note: These procedures are recommendations for the treating 
pulmonologist, and are not mandatory study procedures.
Definition Recommended Follow -up
Symptomatic 
(Moderate to 
Severe)Present for 3 consecutive 
weeks:
Cough (CTC grade 2 or 3)
OR
Dyspnea (Borg CR10 
Scale grade 3 or above)History, physical examination, and chest 
X-ray
DLCOmeasurement
If no clear alternative diagnosis can be made, 
e.g. infection or cardiac failure, then further 
assessment by a local pulmonologist 
(including chest HRCT) is recommended:
If HRCT shows ground glass opacity, and 
no alternative diagnosis, BAL to confirm 
diagnosis e.g.PAP
Repeat chest HRCT 3 -6 months later to 
monitor resolution.
Asymptomatic Present for 3 consecutive 
weeks:
Reduction in D LCO >15% 
relative to baseline value
(NB: A subject’s baseline 
DLCO value will be taken as the 
lowest value obtained from 
the Screening or Day 1 
assessment.)Repeat spi[INVESTIGATOR_515279] D LCO
(weekly intervals)
If the second or third D LCOreturns to a 
normal range ( i.e.,change from baseline 
≤15%), D LCOshould be repeated one 
week later to ensure stability
If D LCOdecrease is persistent:
History & phy sical examination & chest 
X-ray
If no alternative diagnosis e.g. infection 
or cardiac failure, then assessment by 
a pulmonologist and chest HRCT is 
recommended
If HRCT shows ground glass opacity, and 
no alternative diagnosis, BAL to confirm 
diagnosis e.g.PAP
Repeat chest HRCT 3 -6 months later to 
monitor resolution. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10710].6.2. Management of Study Medications During Pulmonary  
Assessment
As described above, study  medication should be withdrawn for the remainder of the 
study whilst the subject undergoes these additional pulmonary investigations.
12.6.3. Central Review  of Pulmonary  Investigations
If a chest HRCT is performed, the HRCT report should be forwarded to [COMPANY_004] and a cop y 
of the images may  be requested by  [CONTACT_515331] b y a third party .
If the subject undergoes a broncho -alveolar lavage (BAL) assessment, the report should 
be forwarded to [COMPANY_004].  If biopsies are taken during the BAL procedure, the prepared 
histologic slides may  be requested by  [CONTACT_515332] b y a third party .
On a case -by-case basis, the reports/images/samples from other pulmonary  investigations 
may also be requested by [CONTACT_515333]  a third part y, and particularl y in 
cases where there is a suspi[INVESTIGATOR_515280].‘Reactive’ algorithms
•History & physical examination
•[COMPANY_004]3196165 stopped
•Assessment by [CONTACT_420250]
•CXR / chest HRCT
•BAL + repeat chest HRCT if indicatedor
Pulmonary safety strategy
Symptomatic 
Cough :  CTC grade 2 or 3, for 3 
consecutive weeks
or 
Dyspnea: Borg scale grade 3  or 
greater, for 3 consecutive weeksAsymptomatic
>15% from
baseline DLCO for 
3 weeks 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10711].6.4. Adjudication Process for Suspected Cases of Pulmonary  
Alveolar Proteinosis
There will be an adjudication process for: 1) all events of PAP, 2) all cases suspi[INVESTIGATOR_515281], 3) all events that trigger the pulmonary  assessment algorithms where an alternative 
diagnosis cannot be made.  [COMPANY_004] may  request additional case information (e.g. medical 
history , imag ing data, clinical investigation reports) to assist the adjudication.  
The adjudication process will be performed b y external experts who are independent of 
[COMPANY_004], and will also include independent review of radiological investigations. 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10712].7. Appendix 7 –Common Terminology  Criteria for A dverse 
Events (CTCA E): Cough
Taken from CTCAE version 4.03 (June 14, 2010): Respi[INVESTIGATOR_696] , thoracic and mediastinal 
disorders.
Respi[INVESTIGATOR_696] , thoracic and mediastinal disorders
Grade
Adverse 
Event1 2 3
Cough Mild sy mptoms ; non -
prescription 
intervention indicatedModerate 
symptoms ; medical 
intervention indicated; 
limiting instrumental 
ADLSevere sy mptoms ; 
limiting self care ADL
Definition : A disorder characterized by [CONTACT_5157], often repetitive, spasmodic contraction 
of the thoracic cavity, resulting in violent release of air from the lungs and usually 
accompanied by a distinctive sound.
ADL : activities of dail y living 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10713].8. Appendix 8 –Average Pain NRS 2017N347456_00
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by [CONTACT_515334].
2015N242468_02 CONFIDENTIA L
[PHONE_10714].9. Appendix 9 –Worst Pain NRS 2017N347456_00
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by [CONTACT_515334].
2015N242468_02 CONFIDENTIA L
[PHONE_10715].10. Appendix 10 –Patient Global A ssessment of Disease 
Activity (PtGA ) 2017N347456_00
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by 
[CONTACT_14561].
2015N242468_02 CONFIDENTIA L
[PHONE_10716].11. Appendix 11 –Physician Global Assessment of Disease 
Activity (PhGA ) 2017N347456_00
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by [CONTACT_515334].
2015N242468_02 CONFIDENTIA L
[PHONE_10717].12. Appendix 12 –Patient Post- Treatment Interview
Title: A multi -centre Phase IIa double- blind, placebo -controlled study to investigate the 
efficacy and safety of [COMPANY_004]3196165 in subjects with inflammatory hand osteoarthritis
Patient Post -Treatment Interview
Instructions for Interviewer :  
1.At the beginning of th e interview, please confirm the patient’s study number.
2.Text written in bold is to be read verbatim to each subject. 
3.Text written in [italics] is an instruction to the interviewer.  
4.Probes are to be used as needed to encourage the subject to provide full
responses to each of the questions.  They should be used if the subject gives an 
incomplete or unclear response or explanation with the initial question.
5.Actively listen during the interview and take notes as necessary. 
INTRODUCTION:
Hello, my  name [CONTACT_832] [ state first name] and I will be asking y ou some questions about 
your experience with medications in this study. The interview will be recorded and 
a transcript will be developed. In order to protect y our confidentiality , only  your 
study  number will be incl uded in the transcript. You are free to stop the interview 
at any  time if y ou decide y ou no longer wish to participate.
The follo wing questions have been developed to provide information on patient 
experiences with medications.  It is important that y ou gi ve your best answers, so 
please listen carefully  to each question before y ou respond.  
Are you ready  to begin? 
[Pause and assess subject readiness to continue] 
I will no w turn on the recorder.  Can y ou confirm that y ou agree to have this 
intervie w audio -recorded? [Wait for interviewee to consent; if consent is not provided, 
end the interview.]
This is study number 204851, the date is [state date] , and I am interviewing 
participant number [state participant number] . 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10718].Thinking back to when you first entered this study , can y ou describe the 
symptoms y ou w ere experiencing at that time?
[For each symptom mentioned ask:]
1a. [Probe]: When did y ou firs t experience [restate symptom] ?
Was [restate symptom] constant or did it vary /come and go?
How  long did [restate symptom] last?
Please describe the severity  of [restate symptom] ?
2.Since the beginning of the study ,what changes have y ou experienced?
2a. [Probe]: For example, have y ou experienced any:
Changes in y our sy mptoms?
New symptoms?
Changes in ho w you have been feeling?
Changes in y our ability to do daily  activities (wash, dress, eat, 
household chores)
[For each symptom/change mentioned:]
2b. [Probe]: How  did [restate symptom] change? OR You mentioned a new 
symptom –can you please describe [restate symptom] (e.g. 
onset, frequency , severity , duration), OR You mentioned that 
the way  you were feeling changed. What was this change like? 
OR You men tioned your ability  to do daily  activities changed. 
What was this change like?
2c. [Probe]: On a scale of 0 to 10, where 0 is not at all important and 10 is 
extremely  important, how important was this change to 
you?What are the reasons y ou selected X?
2d.[Probe]: [if important] What are the reasons this change was important?
2e.[Probe]: Did y ou experience any  other sy mptoms or changes since 
starting the study ? [Ask follow -up probes 2b through 2d above for 
each symptom / change]
2f.[Probe]: Of the cha nges y ou experienced, [read back list of changes] , 
which was most important to y ou?  
2g. [Probe]: What were the reasons it was most important to y ou?  
2h. [Probe] :Which change was the next most important?  [Have participant 
rank order all remaining sy mptoms/changes]
[If patient DOES NOT spontaneously mention each of the following symptoms and 
changes -pain in their affected hand(s),stiffness in their affected hand(s), swelling in their 
affected hand(s), ability to do daily activities -ask the relevant questions from questions 
3 -6.]   2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
101[If patient DOES spontaneously mention pain in their affected hand(s), stiffness in their 
affected hand(s), swelling in their affected hand(s), ability to do daily activities move on 
to question 7.]
3.Since the beginning of the study , did y ou have any  changes in the pain of 
your hand(s)?
3a. [Probe]: What were these changes like?
3b. [Probe]: How  important were the changes to y ou?
3c. [Probe]: [If important] What were the reasons these changes were 
important to y ou?  
4.Since the beginni ng of the study, did you have any changes in the stiffness 
of your hand(s)?
4a. [Probe]: What were these changes like?
4b. [Probe]: How  important were the changes to y ou?
4c. [Probe]: [If important] What were the reasons these changes were 
important to y ou?
5.Since the beginning of the study , did y ou have any  changes in the swelling 
of your hand(s)?
5a. [Probe]: What were these changes like?
5b. [Probe]: How  important were the changes to y ou?
5c. [Probe]: [If important] What were the reasons these changes were 
important to y ou?
6.Since the beginning of the study , did y ou have any  changes in y our ability  
to perform daily  activities (for example: washing, dressing, eating, doing 
household chores)
6a. [Probe]: What were these changes like?
6b. [Probe]: How  important were the changes to y ou?
6c. [Probe]: [If important] What were the reasons these changes were 
important to y ou?
7.Overall, ho w satisfied or dissatisfied were y ou with changes in y our 
symptoms y ou may  have experienced during treatment in this study ?
      [Show the subject the response scale on response scale sheet]
Very 
dissatisfiedDissatisfied Not satisfied or 
dissatisfiedSatisfied Very satisfied
1 2 3 4 5
7a. [Probe]: What were the reasons y ou selected [restate response] ? 2017N347456_00
2015N242468_02 CONFIDENTIA L
[PHONE_10719].How  does the medication you received in this study  compare to medicines 
you have taken in the past for y our hand arthritis (hand osteoarthritis)?
8a. [Probe]: Do y ou prefer the study  medication or medications y ou have 
taken in the past for y our hand arthritis (hand osteoarthritis)?
What are the reasons you prefer [insert preferred medication] ?
8b. [Probe]: What do y ou like more about the study  medication?   
8c. [Probe]: What do y ou like more about y our past medications?
9.Would y ou be interested in taking the study  medication in the future if it 
were available?
[Show the subject the response scale on response scale sheet]
Not at all 
interestedA little 
interestedModerately 
interestedVery 
interestedExtremely 
interested
1 2 3 4 5
9a. [Probe]: What about the study  medication makes y ou interested in
continuing to take it?
9b. [Probe]: What about the study  medication makes y ou not interested in 
continuing to take it?  
9c. [Probe]: If there was one thing you could change about the study  
medication, what would it be?  What is the reason y ou w ould 
want to make that change?
10.Considering how this study  was organized in terms of office visits, lab 
visits, the patient questionnaires, and in -person and phone conversations 
with nurses/doctors, what did y ou like the best about being in the study ?   
10a. [Probe]: What is the reason you liked that best?
10b. [Probe]: What did y ou like least about being in the study? What is the 
reason y ou liked that least?
10c. [Probe]: Are there any  changes you w ould suggest for future studies to 
make the experience better for y ou?
Thank y ou foryour participation in this interview.
[Interviewer:  Turn off recorder ] 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
[ZIP_CODE].13. Appendix 13 –Country  Specific Requirements
None 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
[ZIP_CODE].14. Appendix 14 –Protocol A mendment Changes
AMENDMENT [ADDRESS_667800] of Specific Changes
Section 12.5.1 Males:
Correction tocontraceptive requirements:
ADDED TEXT
Male subjects should not donate sperm during the course of the study and should 
follow local guidelines thereafter.
Section 12.5. [ADDRESS_667801] of Highly  Effective Methods for Avoiding 
Pregnancy  in Females of Reproductive Potential (FRP)
Correction tocontraceptive requirements:
ADDED TEXT
If using hormonal contraceptives, including oral, injections, implants, and patches, a 
second ary method of contraception must be used.
Section 12.12 A ppendix 12 –Patient Post -Treatment Interview
Minor correction of question number in post -treatment interview guidance Q uestion 2:
PREVI OUS TEXT
[If patient DOES spontaneously mention pain in their affected hand(s), stiffness in their 
affected hand(s), swelling in their affected hand(s), ability to do daily activities move on 
to question 8.]
REVI SED TEXT
[If patient DOES spontaneously mention pain in their affected hand(s), stiffness in their 
affected hand(s), swelling in their affected hand(s), ability to do daily activities move on 
to question 7.] 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
105AMENDMENT 0 2
Where the A mendment A pplies
Applicable to a ll countries and all sites.
Summary  of A mendment Changes with Rationale
Amendment of inclusion criteria, #2, #3 and #5, to allow enrolment of subjects who 
are intolerant to analgesics or NSAIDs, and to remove the requirement that the same 
joints must be affected at screening and randomi zation.
Clarification of exclusion #9 (and Section 7.4.6) to ensure averaged QTc values are 
used throughout stud y. 
Amendment of exclusion #19(d) to allow enrolment of subjects with MR-conditional 
inner ear implants.
Additi on of two planned interim analyses to Section 9.3 and update to planned 
analysis methods in Section 9.4.
Update to Time and Events table in Section 7.1.2 and Section 7.1.3, to increase visit 
Window for Day  3 and to add PK sampling on Day  85 (Week 12 visit) and Day  155 
(Week 22 visit).
Correction to Section 6.10.[ADDRESS_667802] 22 day s prior to Day  1.
Update to Section 6.4 (Blinding) to allow unblind sponsor staff during interim 
analyses.
Correction of Se ction 4.6, Figure 1, to indicate that follow -up takes place at Week 
22.
Clarification in Section 7, that the requirement to complete PROs before any  other 
assessments applies to assessments at the main study site.
Update to Section 7.3.[ADDRESS_667803] not be the Joint Assessor.
Clarification of MRI rescan requirements and increase in the allowed MRI rescan 
window from 7 to 10 days, in Section 7.6.1.
Correction of table in Section 12.6.[ADDRESS_667804] DLCO measurement at 
screeni ng or baseline is used as the reference for any  pulmonary  safet y monitoring.
Correction of “Pulmonary Safety  Strategy ” diagram in Section 12.6.1, removing 
mention of “MTX”, because this is not used in this study .
Update of primary  and secondary  medical mon itor details.
List of Specific Changes
Amendment of inclusion criteria, #2, #3 and #5, to allow enrolment of 
subjects who are intolerant to analgesics or NSA IDs, and to remove  2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667805] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY 
2. Meets ACR classification of OA and ha ve not responded to analgesics (level 1 and 2) 
or to NSAIDs for at least [ADDRESS_667806] two swollen 
and tender PIP and/or DIP joints in the affected hand* ; with the same two joints 
affected at both screening and randomization.
4.Signs of inflammation such as s ynovitis in the MRI scan of the affected hand*.
5.Must have a patient’s self assessment of 24h average hand pain intensity  at baseline
of at least ‘5’ on an 11 -point NRS (0 -10), calculated as an average using data from 
the [ADDRESS_667807] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY 
2. Meets ACR classification of OA and is intolerant to, or has not responded to 
analgesics (level 1 and 2) or to NSAIDs for at least [ADDRESS_667808] active disease with at leas t two swollen and tender PIP and/or DIP joints in 
the affected hand* .
4.Signs of inflammation such as s ynovitis in the MRI scan of the affected hand*.
5.Must have a patient’s self assessment of 24h average hand pain intensity  of at least 
‘5’ on an 11- point NRS (0-10), calculated as an average using data from the 7 day s 
prior to assessment date.
Clarification of exclusion #9 (and Section 7.4.6) to ensure averaged 
QTc values are used throughout study .
PREVI OUS TEXT
9.QTc > 450 msec or QTc > 480 msec in subjects with Bundle Branch Block
REVI SED TEXT
9. QTc > 450 msec or QTc > 480 msec in subjects with Bundle Branch Block based on 
averaged values of triplicate electrocardiograms obtained over a brief (e.g. 5 -10 
minute) recording period 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
107Amendment of exclusion #19(d) to allow enrolment of subjects with 
MR-conditional inner ear implants.
PREVI OUS TEXT
19.Contraindication to MRI  scanning (as assessed by  [CONTACT_515306] y questionnaire) 
which includes but not limited to:
d.Inner ear implants
REVI SED TEXT
19.Contraindication to MRI  scanning (as assessed b y local MRI  safet y questionnaire) 
which includes but not limited to:
d.Inner ear implants, except MR -conditional implants scanned within 
manufacturer guidelines
Addition of two planned interim analy ses to Section 9.3 and update to 
planned analysis methods in Section 9.4 .
PREVI OUS TEXT
9.3 Data Analysis Considerations
9.3.1 Analysis Populations
Intent to Treat (ITT) population: The I TT population is defined as all subjects who were 
randomised to treatment and who received at least one dose of stud ytreatment.
Pharmacokinetic (PK) population: The PK population is defined as all subjects who were 
randomised to treatment, who received at least one dose of study  treatment and who have
at least one valid PK assessment.
9.3.2 Interim A nalysis
No interim anal yses are planned for this study .
9.4 Key Elements of A nalysis Plan
Full details of all anal yses will be provided in the RAP.
9.4.1 Primary  Analyses
The primary  endpoint will be anal ysed using a repeated measures model (MMRM) 
adjusted for baseline pain score, treatment group, visit and the visit by  [CONTACT_515323], patient as a random effect and day  within patient as a repe ated 
effect, using an unstructured covariance matrix.  The point estimates and corresponding 
95% confidence intervals for the treatment differences will be constructed, using the 
residual error from the repeated measures model.  Least squares means and 95%
confidence intervals over time for each treatment group will be plotted.  Further  2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667809] of missing data and non -
parametric anal yses may  be conducted if the normality  assumption does not hold.
9.4.2 Secondary Analyses
Continuous endpoints will be anal ysed using the same methods as the primary  endpoint.
Binary  endpoints, e.g. the proportion of subjects that achieve a 30% reduction in the Pain 
NRS score from baseline, will be summarised using counts and proporti ons in remission 
and anal ysed using a logistic regression analy sis adjusted for treatment group and 
baseline Pain NRS score and will be used to test the treatment comparison of 
[COMPANY_004]3196165 versus placebo.  An estimate of the odds ratio, the corresponding p -value 
and 95% confidence interval will be summarised. Subjects with missing Pain NRS 
scores will be considered as non -responders.
REVI SED TEXT
9.3 Data Analysis Considerations
9.3.1 Analysis Populations
Intent to Treat (ITT) population: The I TT population is define d as all subjects who were 
randomised to treatment and who received at least one dose of stud y treatment. This 
population will be based on the randomised treatment group.
Safety population: The safety population is defined as all subjects who receive at 
least one dose of study treatment. This population will be based on the actual 
treatment received.
Pharmacokinetic (PK) population: The PK population is defined as all subjects who are 
in the ‘Safety’ population and who have at least one valid PK assessment.
9.3.[ADDRESS_667810].  Unblin ded 
data will be shared with members of Clinical Pharmacology Modelling and 
Simulation (CPMS), Clinical Statistics and [COMPANY_004] study team members who have no 
involvement in the acquisition of the data or direct contact [CONTACT_190063].  No other 
members of the [COMPANY_004] study team will be unblinded to this data. 
Another formal interim analysis may be conducted on the key safety, primary 
efficacy and key secondary endpoints in this study.  The purpose of this interim will 
be to help with decision -making regarding the subsequent clinical development of 
[COMPANY_004]3196165 fo r OA.  The timing of this analysis will be once a minimum of [ADDRESS_667811] completed day 43 (Week 6).  Full details will be provided in the RAP 
which will be available prior to the data being unblinded.  Unblinded data will only 
be shared with selected members of the [COMPANY_004] study team.  No members of the [COMPANY_004]  2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667812] treatment allocations.
9.4 Key Elements of A nalysis Plan
Full details of all anal yses will be provided in the RAP.
9.4.1 Primary  Analyses
The primary  endpoint will be anal ysed using a repeated measures model (MMRM) 
adjusted for b aseline pain score, treatment group, visit and the visit by  [CONTACT_515323], patient as a random effect and day  within patient as a repeated 
effect, using an unstructured covariance matrix.  The point estimates and correspondin g 
95% confidence intervals for the treatment differences will be constructed, using the 
residual error from the repeated measures model.  Least squares means and 95% 
confidence intervals over time for each treatment group will be plotted.  Further 
sensitiv ity anal yses will be conducted to assess the impact of missing data and non -
parametric anal yses may  be conducted if the normality  assumption does not hold.
9.4.2 Secondary  Analyses
Continuous endpoints will be anal ysed using the same methods as the primary  endpoint.
Binary  endpoints, e.g. the proportion of subjects that achieve a 30% reduction in the Pain 
NRS score from baseline, will be summarised using counts and proportions in remission 
and anal ysed using a Generalised Estimating Equation (GEE) model comparing 
[COMPANY_004]3196165 with p lacebo at each time point.   Subjects with missing Pain NRS scores 
will be considered as non -responders.
Update to Time and Events table in Section 7.1.2 and Section 7.1.3, to 
increase v isit Window for Day  3 and to add PK sampling on Day  85 
(Week 12 visit) and Day  155 (Week 22 visit).
ADDED TEXT
Section 7.1.2 Treatment period Time and Events table
Addition of “( 1d)” window to Day  3 PK biomarker visit.
Addition of a “X” to “ PK sampl ing” row, on Day 85 treatment visit. 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
110Section 7.1.3 Follow -up visit and early  withdrawal* procedures list
Addition of “ PK sampl ing” to Subject Follow -up Visit Task L ist.
Correction to Section 6.10.2. to state that opi[INVESTIGATOR_515282] 22 day s prior to Day  1.
PREVI OUS TEXT
6.10.2 Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_515283] (Screening 
Day 1, see Time and Events table, Section 7.1) until after completion of the Week [ADDRESS_667813] also be discontinued for the stated time 
prior to Day  1 as follows:
Hydroxy chloroquine must be discontinued at least 3 weeks prior to Day  1.
NSAIDs (both s ystemic and topi[INVESTIGATOR_2855]) must be discontinued at least 22 day s prior to 
Day 1.
Opi[INVESTIGATOR_515265] -formulated medicines of paracetamol and 
opi[INVESTIGATOR_515266] 12days prior to Day  1.
REVI SED TEXT
6.10.2 Prohibited Medications and Non -Drug Thera pi[INVESTIGATOR_515264] 1 (randomization) until after 
completion of the Week [ADDRESS_667814] also be discontinued for the stated time 
prior to Day  1 (randomization) as follows:
Hydroxy chloroquine must be discontinued at least 3 weeks prior to Day  1.
NSAIDs (both s ystemic and topi[INVESTIGATOR_2855]) must be discontinued at least 22 day s prior to 
Day 1.
Opi[INVESTIGATOR_515265] -formulated medicines of paracetamol and 
opi[INVESTIGATOR_515266] 22days prior to Day  1.
Update to Section 6.4 (Blinding) to allow unblind sponsor staff during 
interim analy ses.
PREVI OUS TEXT
6.4 Blinding
The study  will be double -blind, which means that the investigator and trial staff at site 
(apart from the unblinded administrator [study  co-ordinator or nurse]), subject, and  2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
111sponsor personnel (apart from unblinded study  monitor) will be blinded to the trial 
treatment allocated to each individual subject. 
There will be an unblinded ad ministrator (study  co-ordinator or nurse) who will prepare 
and administer the study  treatment.
The following will apply .
REVI SED TEXT
6.4 Blinding
The study will be double -blind (sponsor unblind), which means that the subject, 
investigator and trial staff at site (apart from unblinded administrator(s) and 
pharmacy staff), will be blinded to the trial treatment allocated to each individual 
subject. In addition, the sponsor central and local study teams will be blinded to 
treatment allocations, except for roles required to be ‘unblind’ in order to manage 
study conduct and oversight (including unblinded monitor(s)) and roles specified in 
the Reporting an d Analysis Plan (RAP) as involved with the preparation and review 
of the planned interim analyses. 
The RAP, which will be approved prior to the first unblinding, will identify the 
specific [COMPANY_004] individuals involved; outline in detail the activities of the interim 
analyses, and how the integrity of the study will be maintained.
At sites, there will be a t least one unblinded administrator (study  co-ordinator or nurse)
who will prepare and administer the study  treatment.
In the case of emergency unblinding (eg. through RAMOS NG or [COMPANY_004] Clinical 
support help desk), the following will appl y:
Correction of Section 4.6, Figure 1, to indicate that follow -up takes 
place at Week 22.
PREVI OUS FIGURE
 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
112REVI SED FIGURE
Clarification in Section 7, that the requirement to complete PROs 
before any  other assessments, applies to ass essments at the main 
stud y site.
PREVI OUS TEXT
PROs must be administered prior to an y other assessments being performed to 
avoid influencing subjects.
REVI SED TEXT
PROs must be administered prior to an y other assessments being performed (at 
the main study site) to avoid influencing subjects.
Update to Section 7.3.1. to clarify  which site staff must not be the 
Joint A ssessor.
PREVI OUS TEXT
Joint Assessments
To prevent potential unblinding because of observed efficacy  changes, a “dual assessor”
approach will be used to evaluate efficacy  and safety .
REVI SED TEXT
Joint Assessments
To prevent potential bias because of observed efficacy  changes, the Joint Assessor must 
not be the treating physician (PI [INVESTIGATOR_11637] -investigator) or the unblinded drug 
administrator.
 2017N347456_00
2015N242468_02 CONFIDENTIA L
[ADDRESS_667815]’s affected wrist (corresponding to the affected hand which is determined 
and documented at screening) will be imaged b y MRI  at screening, week 12 and week 22 
(see Section 7.1). If a scanning failure occurs at any visit, if feasible a resca n is allowed 
within 7days of the failed scan after consultation and agreement with the [COMPANY_004] medical 
monitor. There will be a minimum of [ADDRESS_667816]’s affected hand (corresponding to the affected hand which is determined 
and documented at screening) will be imaged b y MRI  at screening, week 12 and week 22 
(see Section 7.1). If a scanning fail ure occurs at any  visit, if feasible a resca n is allowed 
within 10days of the failed scan after consultation and agreement with the [COMPANY_004] medical 
monitor. There will be a minimum of [ADDRESS_667817] D LCO
measurement at screening or baseline is used as the reference for 
any pulmonary  safety  monitoring.
PREVI OUS TEXT
(NB: A subject’s baseline D LCOvalue will be taken as the highest value obtained 
from the Screening or Day 1 assessment.)
REVI SED TEXT
(NB: A subject’s baseline DLCO value will be taken as the lowest value obtained 
from the Screening or Day 1 assessment.) 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
114Correction of “Pulmonary  Safety  Strategy ” diagram in Section 12.6 .1, 
removing mention of “MTX”, because this is not used in this study .
PREVI OUS FIGURE
‘Reactive’ algorithms
•History & physical examination
•[COMPANY_004]3196165 (+/ -MTX) stopped
•Assessment by [CONTACT_420250]
•CXR / chest HRCT
•BAL + repeat chest HRCT if indicatedor
Pulmonary safety strategy
Symptomatic 
Cough :  CTC grade 2 or 3, for 3 
consecutive weeks
or 
Dyspnea: Borg scale grade 3  or 
greater, for 3 consecutive weeksAsymptomatic
>15% from
baseline DLCO for 
3 weeks 2017N347456_00
2015N242468_02 CONFIDENTIA L
204851
115REVI SED FIGURE
Update of primary  and secondary  medical monitor details.
PREVI OUS TABLE
Role Name [CONTACT_428260] -hours 
Phone/Cell/
Pager NumberFax Number Site Address
Primary 
Medical 
Monitor [COMPANY_004],
Ironbridge Road,
Stockley Park West, 
Uxbridge.
UB11 1BT 
Secondary 
Medical 
Monitor[COMPANY_004] Medicines 
Research Centre,
Gunnels Wood 
Road, Stevenage, 
Herts. SG1 2NY‘Reactive’ algorithms
•History & physical examination
•[COMPANY_004]3196165 stopped
•Assessment by [CONTACT_420250]
•CXR / chest HRCT
•BAL + repeat chest HRCT if indicatedor
Pulmonary safety strategy
Symptomatic 
Cough :  CTC grade 2 or 3, for 3 
consecutive weeks
or 
Dyspnea: Borg scale grade 3  or 
greater, for 3 consecutive weeksAsymptomatic
>15% from
baseline DLCO for 
3 weeks 2017N347456_00
[COMPANY_003]
2015N242468_02 CONFIDENTIA L
204851
116REVI SED TABLE
Role Name [CONTACT_515335] -hours 
Phone/Cell/
Pager 
NumberFax Number Site Address
Primary 
Medical 
Monitor [COMPANY_004] Medicines 
Research Centre,
Gunnels Wood 
Road, Stevenage, 
Herts. SG1 2NY
Secondary 
Medical 
Monitor[COMPANY_004],
Ironbridge Road,
Stockley Park 
West, Uxbridge.
UB11 1BT  2017N347456_00
[COMPANY_003]